Title of Invention

"PNA MONOMER AND PRECURSOR "

Abstract The present invention relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers: (I) wherein E is nitrogen or C-R'; J is sulfur or oxygen; R', Rl, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl, halogenated alkoxy, phenyl or halogenated phenyl, RS is H or protected or unprotected side chain of natural or unnatural a-amino acid; and B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases in the presence of thiol.
Full Text BACKGROUND OF THE INVENTION
[0001] 1. Field of the Invention:
[0002] The present invention relates to monomers suitable for the preparation of PNA oligomers. The present invention also relates to precursors to the monomers and methods of making the PNA monomers from the precursors. Further, the invention relates to methods of making PNA oligomers using the PNA monomers. [0003] 2. General Background and State of the Art:
[00041 In the last two decades, attempts to optimize the properties of oligonucleotide by modification of the phosphate group, the ribose ring, or the nucleobase have resulted in a lot of discoveries of new oligonucleotide derivatives for the application in the fields of DNA diagnostics, therapeutics in the form of antisense and antigene, and the basic research of molecular biology and biotechnology (U. Engiisch and D. H. Gauss, Angew. Chem. Int. Ed. Engl. 1991, 30, 613-629; A. D. Mesmaeker et al. Curr. Opinion Struct. Biol. 1995, 5, 343-355; P. E. Nielsen, Curr. Opin. Biotech., 2001, 12, 16-20.). The most remarkable discovery is peptide nucleic acid which was reported by the Danish group of Nielsen, Egholm, Buchardt, and Berg (P. E. Nielsen et al., Science, 1991, 254, 1497-1500). PNA is DNA analogue in which an N-(2-amrnoethyl)glycine polyamide replaces the phosphate-ribose ring backbone, and methylene-carbonyl linker connects natural as well as unnatural nucleo-bases to central amine of N-(2-aminoethyl)glycine. Despite radical change io the natural structure, PNA is capable of sequence specific binding to DNA as well as RNA obeying the Watson-Crick base pairing rule. PNAs bind with higher affinity to complementary nucleic acids than their natural counterparts, partly due to the lack of negative charge on backbone, a consequently reduced charge-charge repulsion, and favorable geometrical factors (S. K. Kim et al., J. Am. Chem. Soc, 1993, 115, 6477-6481; B. Hyrup et al., J. Am. Chem. Soc, 1994, 116, 7964-7970; M. Egholm et al., Nature, 1993, 365, 566-568; K. L. Dueholm et al., New J. Chem., 1997,21, 19-31; P. Wittung et al., J. Am. Chem. Soc, 1996,118, 7049-7054; M. Leijon et al., Biochemistry, 1994, 9820-9825.). Also it was demonstrated that the thermal stability of the resulting PNA/DNA duplex is independent of the salt concentration in the hybridization solution (H. Orum et al., BioTechniques, 1995, 19, 472-480; S. Tomac et al., J. Am. Chem. Soc, 1996,118, 5544-5552.). And PNAs can bind in either parallel or
antiparallel fashion, with antiparallel mode being preferred (E. Uhlman et al., Angew. Chem. Int. Ed. Engl., 1996,35, 2632-2635.).
[0005] A mismatch in a PNA/DNA duplex is much more destabilizing than a mismatch in a DNA/DNA duplex. A single base mismatch results in 15 °C and 11 °C lowering of the Tm of PNA/DNA and DNA/DNA, respectively. Homopyrimidine PNA oligomers and PNA oligomers with a high pyrimidine/purine ratio can bind to complementary DNA forming unusually stable PNA2/DNA triple helices (P. E. Nielsen et al., Science, 1991, 254, 1497-1500; L. Betts et al., Science, 1995, 270, 1838-1841; H. Knudsen et al., Nucleic Acids Res., 1996, 24, 494-500.). Although PNAs have amide bonds and nucleobases, PNAs show great resistance to both nuclease and protease. In contrast to DNA, which depurinates on treatment with strong acids and hydrolyses in alkali hydroxides, PNAs are completely acid stable and sufficiently stable to weak bases.
|0006] Generally, PNA oligomers are synthesized using the well established solid phase peptide synthesis protocol. New strategies for monomers have been developed independently by several groups to optimize PNA oligomer synthesis. The preparation of PNA monomers can be divided into the synthesis of a suitably protected N-aminoethylglycine and a suitably protected nucleobase acetic acid derivatives, which is followed by coupling both.
[0007J The first synthetic strategy reported for PNA oligomer synthesis was Merrifield solid phase synthesis using t-Boc/benzyloxycarbonyl protecting group strategy wherein the backbone amino group protected with the t-Boc and the exocyclic amino groups of the nucleobases are protected with the benzyloxycarbonyl (P. E. Nielsen et al., Science, 1991, 254, 1497-1500; M. Egholm et al.,'7. Am. Chem. Soc, 1992,114,9677-9678; M. Egholm et al., J. Am. Chem. Soc, 1992, 114, 1895-1897; M. Egholm et al., / Chem. Soc. Chem. Commun., 1993, 800-801; K.L. Dueholm et al., J. Org. Chem., 1994, 59, 5767-5773; WO 92/20702). PNA monomers protected with t-Boc/benzyloxycarbonyl are now commercially available but are inconvenient to use because repeated treatment with TFA is required for t-Boc deprotection and the harsh HF or trifluoromethanesulfonic acid treatment required for cleavage from the resin and deprotection of benzyloxycarbonyl group from exocyclic amine of nucleobases. Thus, this strategy is not compatible with the synthesis of many types of modified PNA oligomers such as PNA-DNA chimera. Furthermore, the use of hazardous acids, such as HF or trifluoromethanesulfonic acid, is not commercially embraced in view of safety concerns for the operator and the corrosive effect on automation equipment and lines. In addition, the t-Boc/benzyloxycarbonyl protection strategy is differential strategy
which is defined as a system of protecting groups wherein the protecting groups are removed by the same type of reagent or condition, but rely on the different relative rates of reaction to remove one group over the other. For example, in the t-Boc/benzyloxycarbonyl protecting strategy, both protecting groups are acid labile, but benzyloxycarbonyl group requires a stronger acid for efficient removal. When acid is used to completely remove" the more acid labile t-Boc group, there is a potential that a percentage of benzyloxycarbonyl group will also be removed contemporaneously. Unfortunately, the t-Boc group must be removed from amino group of backbone during each synthetic cycle for the synthesis of oligomer. Thus TFA is strong enough to prematurely deprotect a percentage of the side chain benzyloxycarbonyl group, thereby introducing the possibility of oligomer branching and reducing the overall yield of desired product.
10008] In another effort to find a milder deprotecting method for PNA oligomer synthesis that would be compatible with DNA oligomer synthesis, several research groups have developed PNA monomers protected with Mmt/acyl wherein the backbone amino group protected with the Mmt and the exocyclic amino groups of the nucleobases are protected with an acyl group such as benzoyl, anisoyl, and t-butyl benzoyl for cytosine and adenine, or isobutyryl, acetyl for guanine (D. W. Will et al., Tetrahedron, 1995, 51, 12069-12082; P. J. Finn et al., Nucleic Acid Research, 1996, 24,3357-3363; D. A. Stetsenko et al., Tetrahedron Lett. 1996,3571-3574; G.. Breipohl et al., Tetrahedron, 1997, 14671-14686.). [0009] Alternative PNA monomers protected with Fmoc/benzhydryloxycarbonyl are also commercially available wherein the backbone amino group protected with the Fmoc and the exocyclic amino groups of the nucleobases are protected with the benzhydryloxycarbonyl (J. M. Coull, et al., US 6,133,444). But Fmoc/benzhydryloxycarbonyl strategy has several drawbacks such as side reaction during the Fmoc deprotection process and instability of monomer in solution. The most critical side reaction is the migration of the nucleobase acetyl group from the secondary amino function to the free TV-terminal amino function of aminoethylglycine backbone under Fmoc deprotection condition (L.Christensen et al., J. Pept. Sci. 1995, 7,175-183 ). The N-acetyl transfer reactions in every cycles during oligomer synthesis result in accumulation of side products which are hard to separate due to similar polarity and same molecular weight. Also the Fmoc protecting group is very unstable in the presence of trace amine. Thus, the selection of the solvent for the PNA monomers should be cautious. Generally, N-methylpyrrolidone of high quality is recommended. This requires higher cost in the synthesis of PNA oligomer.
[0010) The synthesis of PNA oligomers using Fmoc/benzyloxycarbonyl (S. A. Thomson et al., Tetrahedron, 1995, 6179-6194.) and Fmoc/Mmt (G.. Breipohl et al., Bioorg. Med. Chem. Lett., 1996, 6, 665-670.) protected monomer has also been reported. However, all of these methods have serious drawbacks in terms of monomer solubility and preparation, harsh reaction condition, and side reactions either during monomer synthesis and/or PNA oligomer synthesis.
[0011] In other efforts to find new monomers, cyclic monomers were reported by ISIS and Biocept. The first strategy developed by ISIS replaces protected backbone by morpholinone (U. S. Patent No. 5,539,083), but the strategy has serious drawback in that the hydroxy functional group generated by coupling reaction should be converted to amine functional group in every elongation step during oligomer synthesis. Alternatively, the protected aminoethylglycine part is replaced by N-t-Boc-piperazinone (WO 00/02899). However, this strategy also has several drawbacks in terms of monomer reactivity in oligomerization and the same problems as seen in linear t-Boc strategy as described above. [0012] Despite recent advances, there remains a need for new monomer that increases yield, lowers synthetic cost, and is suitable for automatic and parallel synthesis.
SUMMARY OF THE INVENTION
|0013] The present invention provides novel monomers for increased efficiency, high yield, and convenience during synthesis of PNA oligomers. Another object is to provide PNA monomers that can be conveniently applied to instrumentation such as automated synthesizer for synthesis of PNA oligomers. The novel monomers according to the present invention are compounds having general formula I: [0014]
[0015]
(Formula Removed ) [00161 wherein . (00171 E may be nitrogen or C-R', (0018) J may be sulfur or oxygen,
[0019] R' Rl, R2, R3, R4 may be independently H, halogen such as F, CI, Br or I, CF3, alkyl, preferably C1-C4 alkyl, nitro, nitrile, alkoxy, preferably C1-C4 alkoxy, halogenated. (such as F, CI, Br and 1) alkyl, preferably halogenated C1-C4 alkyl, or halogenated (such as F, CI, Br and I) alkoxy, preferably halogenated C1-C4 alkoxy, phenyl, or halogenated (such as F, CI, Br and 1) phenyl,
(0020) R5 may be H or protected or unprotected side chain of natural or unnatural a-amino acid, and
[0021] B may be a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases in the presence of thiol. In another embodiment, B may be thymine (T), cytosine (C), adenine (A), or guanine (G). [0022] Further in particular, the protecting group for the exocyclic amino function of B has a general formula:
[0023J(Formula Removed )
[0024] The group represented by R7 may have a general formula:
[0025] (Formula Removed )
[0026] The residue represented by Y1-Y10 is independently selected from hydrogen,
halogen, such as F, CI, Br, alkyl, preferably methyl, ethyl, t-butyl, and alkoxy, such as
methoxy, ethoxy, and t-butyloxy.
[0027] In another embodiment, R7 may have a general formula;
(0028] (Formula Removed )
[0029] The residue represented by Z1-Z5 is independently selected from hydrogen, halogen, such as F, CI, Br, alkyl, preferably methyl, ethyl, t-butyl, and alkoxy, sucli as methoxy, ethoxy, and t-butyloxy, and methylene dioxy of adjacent two residues. [0030] In another embodiment, R7 may have a general formula;
10031] (Formula Removed )
|0032) The residue represented by R8 may be alkyl or phenyl.
[0033] Further in particular, the protecting group of B may be benzyloxycarbonyl,
benzhydryloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl,
piperonyloxycarbonyl, or 2-methylthioethoxycarbonyl.
|0034] The invention is also directed to nucleobase B, which may be protected by
piperonyloxycarbonyl derivatives.
[0035] In particular, the invention is directed to a cytosine moiety that is protected by
piperonyloxycarbonyl derivatives having a general formula:
[0036] (Formula Removed )
[0037] The residue represented by Q1-Q5 may be independently selected from hydrogen,
halogen, such as F, CI, Br, and I, nitro, alkyl, such as methyl, ethyl, and t-butyl, and alkoxy,
such as methoxy, ethoxy, and t-butyloxy.
[0038] The invention is also directed to an adenine moiety that is protected by
piperonyloxycarbonyl derivatives having a general formula:
[0039]
[0040] (Formula Removed )
[0041] wherein
[0042] Q1. Q2, Q3, Q4 and Q5 are as defined above.
(0043) The invention is also directed to a guanine moiety that is protected by
piperonyloxycarbonyl derivatives having a general formula:
[0044]
[00451(Formula Removed )
[0046] wherein
J0047J Qi, Q2, Qx Qi and Q5 are as defined above.
|0048]
|00491 The present invention further provides for methods of preparing compounds of
general formula I from compounds of general formula V.
[0050] (Formula Removed )
[00511 wherein
[0052] E, J, Rl, R2, R3, R4, R5 and B are as defined above,
(0053J the protecting group of B when said nucleobase of B has an exocyclic amino
function is also as described above, and
10054] R6 may be H, alkyl, preferably (C1-C4) alkyl (such as methyl, ethyl, and t-butyl),
or aryl.
|0055] In another embodiment, the invention provides for compounds of general
formula V and their preparation methods from compounds of general formula II.
(0056] (Formula Removed ) 100571
(0058] wherein
|0059] E, J, R1, R2, R3, R4, R5, and R6 are as defined above.
[0060] Also, the present invention provides compounds of formula II and their
preparation methods.
[00611 In another embodiment, the invention is directed to a method of making the
compound of formula V, comprising coupling reaction of a compound of formula II with a
nucleobase acetic acid moiety in the presence of non-nucleophilic organic base and a
coupling reagent that is customarily used in peptide synthesis.
{0062] The present invention further provides methods of preparing compounds of
formula I from compounds of general formula IV.
10063] (Formula Removed )
10064] wherein
[0065] E, J, R1.R2, R3, R4, and R5 are as defined above, and
{0066] HX is organic or inorganic acid.
]0067] The present invention also provides compounds of general formula IV and their
free acid form, and their preparation methods.
[0068] The present invention further provides methods of preparing compounds of
general formula IV from compounds of general formula II.
[0069] The invention is also directed to a method of making the compound of formula I,
comprising coupling reaction of a compound of formula IV with a nucleobase acetic acid
moiety in the presence of non-nucleophilic organic base and a coupling reagent that is
customarily used in peptide synthesis.
[0070] The invention is also directed to a method of making the compound of formula I,
comprising cyclizing a compound of formula VI in the presence of a coupling reagent that is
customarily used in peptide synthesis or mixed anhydride.
00711(Formula Removed )
|0072J The entities represented by E, J, Rl, R2, R3, R4, R5, and B are as defined above.
The protecting group of B when said nucleobase of B has an exocyclic amino function is
also as set forth above.
[00731 The invention is directed to a compound of formula II, for which its residues are
defined as above. In particular, the R5 residue may be H or protected or unprotected side
chain of natural a-amino acid. In other embodiments, the compound of formula II may have
the following configuration: Rl, R2, R3, and R4 may be H, E is nitrogen, and J is sulfur. In
other embodiments, Rl, R3, and R4 may be H, R2 may be CI, E is nitrogen, and J is sulfur.
In other embodiments, R3 and R4 may be H, Rl may be CI, R2 may be methoxy, E is
nitrogen, and J is sulfur.
[0074| The invention is also directed to a method of making the compound of formula
II, comprising reacting benzothiazole-2-sulfonylchloride, benzoxazole-2-sulfonylcbJoride
benzo[b]thiophene-2-sulfonylchloride, or benzofuran-2-sulfonylchloride derivative with 2-
aminoethylglycine ester in the presence of non-nucleophilic organic base.
The invention is further directed to a compound having formula IV and its free acid form.
The residues for formula IV are as defined above. In particular, the R5 residue may be H or
protected or unprotected side chain of natural a-amino acid. In other embodiments, the
compound of formula IV may have the following configuration: Rl, R2, R3, and R4 may be
H; E is nitrogen and J is sulfur. In other embodiments, Rl, R3, and R4 may be H, R2 may
be CI, E is nitrogen, and J is sulfur. In other embodiments, R3 and R4 may be H, R1 may be
CI, R2 may be methoxy, E is nitrogen, and J is sulfur.
[00751 The invention is further directed to a method of making the compound of
formula IV, comprising cyclizing a compound of formula III in the presence of a coupling
reagent that is customarily used in peptide synthesis or mixed anhydride, followed by
deprotection of a protection group such as t-Boc in acid.
[0076] (Formula Removed )
|0077J The entities represented by E, J, RI, R2, R3, R4, and R5 are as defined above. (0078| The invention is also directed to a method of making PNA oligomer, comprising linking together the compound of formula I.
|0079) It is to be understood that the "R" groups, and E and J designations cited above apply to all of the compounds of formulae I-VI. It is also to be understood that the designations also apply to the compounds as they undergo the processes of the invention. [0080] These and other objects of the invention will be more fully understood from the following description of the invention, the referenced drawings attached hereto and the claims appended hereto. It is further to be understood that the chemical formulae as labeled in the figures serve as representative embodiments. The inventive chemical formulae are discussed throughout the specification. The recited chemical formulae in the figures are not meant to limit the scope of the recited compounds in any way.
BRIEF DESCRIPTION OF THE DRAWINGS
[0081] The present invention will become more fully understood from the detailed
description given herein below, and the accompanying drawings which are given by way of
illustration only, and thus are not limitative of the present invention, and wherein;
[0082] FIGURE 1 shows a chart of the chemical structures of naturally and non-
naturally occurring nucleobases useful for DNA recognition.
[0083] FIGURE 2 shows another chart of the chemical structures of naturally and non-
naturally occurring nucleobases useful for DNA recognition.'
[0084] FIGURE 3 shows a schematic representation of the synthesis of protected
backbone.
[0085] FIGURE 4 shows a schematic representation of the synthesis of protected
piperazinone as a precursor for monomer.
[0086] FIGURE 5 shows a schematic representation of the synthesis of PNA monomer.
[0087] FIGURE 6 shows a schematic representation of the alternative synthesis of PNA
monomer.
(0088) FIGURE 7 shows schemes of preparation of nucleobases protected with
piperonyloxycarbonyl.
[0089] FIGURE 8 shows a schematic representation of the synthesis of PNA thymine
monomer.
[0090] FIGURE 9 shows a schematic representation of the alternative synthesis of PNA
thymine monomer.
[0091 j FIGURE 10 shows a schematic representation of the synthesis of PNA cytosine
monomer
[0092] FIGURE 11 shows a schematic representation of the alternative synthesis of
PNA cytosine monomer.
[0093] FIGURE 12 shows a schematic representation of the synthesis of PNA adenine
monomer.
[0094] FIGURE 13 shows a schematic representation of the alternative synthesis of
PNA adenine monomer.
[0095J FIGURE 14 shows a schematic representation of the synthesis of PNA guanine
monomer.
[0096] FIGURE 15 shows a schematic representation of the alternative synthesis of
PNA guanine monomer.
[0097] FIGURE 16 shows a schematic representation of the PNA oligomer synthesis
from PNA monomers.
[0098] FIGURE 17 shows HPLC and MALDI-TOF results for synthesized oligomer
SEQ ID NO: 1
[0099] FIGURE 18 shows HPLC and MALDI-TOF results for synthesized oligomer
SEQ ID NO: 2
100100] FIGURE 19 shows HPLC and MALDI-TOF results for synthesized oligomer
SEQ ID NO: 3
[00101] FIGURE 20 shows HPLC and MALDI-TOF results for synthesized oligomer
SEQ ID NO: 4
[00102] FIGURE 21 shows HPLC and MALDI-TOF results for synthesized oligomer
SEQ ID NO: 5
[00103| FIGURE 22 shows HPLC and MALDI-TOF results for synthesized oligomer-
SEQ ID NO: 6
[00104] FIGURE 23 shows HPLC and MALDI-TOF results for synthesized oligomer
SEQ ID NO: 7
(00105) FIGURE 24 shows HPLC and MALDI-TOF results for synthesized oligomer SEQ ID NO: 8
|00106] FIGURE 25 shows HPLC and MALDI-TOF results for synthesized oligomer SEQ ID NO: 9
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[00107] It is to be understood that the formulae depicted in the drawings are merely exemplified versions, and where a particular formula is referred to in the claims, the version discussed in the text of the specification is meant.
[00108] In the present invention, benzothiazole-2-sulfonyl, benzo[b]thiophene-2-sulfonyl, benzoxazoIe-2-sulfonyl, or benzofuran-2-sulfonyl group of compounds having general formula I play an important role not only as protecting groups of amine of backbone but also as activating groups for coupling reaction. The monomers having described characteristics are useful for the synthesis of PNA oligomers by manual or automated synthesizer and the preparation of PNA oligomer library by combinatorial chemistry. Nucleobase B in the general formula I is naturally attached at the position found in nature, i.e., position 1 for thymine or cytosine, and position 9 for adenine or guanine, as well as for non-naturally occurring nucleobase (nucleobase analog), or nucleobase binding moiety. Some nucleobases and illustrative synthetic nucleobases are shown in FIG. 1 and FIG. 2. [00109] Preparation of Protected Backbones
[00110] The first step for the preparation of novel monomers having general formula I is synthesis of A/-[2-(benzothiazole, benzoxazole, benzo[b]thiophene, or benzofuran-2-sulfonylamino)-ethyl]-glycine derivatives having the formula II: [00111]
[00112] (Formula Removed )
[00113] wherein E is nitrogen and J is sulfur for N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-glycine derivatives; E is nitrogen and J is oxygen for N-[2-(benzoxazole-2-sulfonyIamino)-ethyl]-glycine derivatives; E is C-R' and J is sulfur for N-[2-(benzo[b]thiophene-2-sulfonylamino)-ethyl]-glycine derivatives; E is C-R' and J is oxygen for N-[2-(benzofuran-2-sulfonylamnio)-ethyl]-glycine derivatives; and R\ Rl, R2, R3, R4, R5, and R6 are as defined above.
[00114] Derivatives having formula II are generally synthesized by selective reaction of primary amine of 2-aminoglycine derivatives with sulfonyl chloride compounds having the general formula:
|00115] (Formula Removed )
[00116] wherein E is nitrogen and J is sulfur for benzothiazole-2-sulfonyl chloride derivatives; E is nitrogen and J is oxigen for benzoxazole-2-sulfonyl chloride derivatives; E is C-R' and J is sulfur for benzo[b]thiophene-2-sulfonyl chloride derivatives; E is CH and J is oxygen for benzofuran-2-sulfonyl chloride derivatives; and [00117| R', Rl, R2, R3, and R4 are as defined above.
[00118] For an example of preparing derivatives having formula II, N-[2-(Benzothiazole-2-sulibnylamino)-ethyl]-glycine derivatives are synthesized by selective reaction of primary amine of 2-aminoglycine derivatives prepared by known methods (for instance, where Rl is H, see S. A. Thomson et al., Tetrahedron, 1995, 6179-6194; where R5 is a side chain of a protected or unprotected natural or unnatural amino acid, see A. Puschl et al., Tetrahedron Lett., 1998, 39, 4707-4710). Benzothiazole-2-sulfonyl chloride derivatives are prepared by known methods (E, Vedejs, etal.,7. Am. Chem. Soc., 1996, 118,9796-9797.). [00119] The coupling reaction for the preparation ofN-[2-(benzothiazole, benzoxazole, benzo[b]thiophene, or bcnzofuran-2-sulfonylamino)-ethyl]-glycine derivatives is performed by slow addition of benzothiazole-2-suIfonyl chloride, benzoxazole-2-sulfonyl chloride, benzo[b]thiophene-2-sulfonyl chloride, or benzofuran-2-sulfonyl chloride to a solution of N-(2-aminoethyl)-glycine derivatives in the presence of non-nucleophilic organic base at ambient temperature. Examples of solvents of above reaction include without limitation water, toluene, benzene, ethylacetate, tetrahydrofuran, diisopropylether, diethylether, dichloromethane, chloroform, carbon tetrachloride, and acetonitrile. Preferred solvent is dichloromethane. Examples of non-nucleophilic organic bases include, but are not limited to, triethylamine, tripropylamine N,N-diisopropylethylamine, N-methylmorpholine, and N-ethylmorpholine. Preferred non-nucleophilic organic base is triethylamine. After completion of the reaction by monitoring by thin layer chromatography (TLC), the reaction mixture is washed with water, dried, and evaporated in reduced pressure to give the desired product. [00120] Preparation of l-(benzothiazole, benzoxazole, benzo[b]thiophene or benzofuran-2-sul fonyl)-piperazin-2-ones
[00121] The first precursor synthons having formula IV for synthesis of monomers having general formula I are prepared fromN-[2-(benzothiazole, benzoxazole, benzo[b]thiophene, or benzofuran-2-sulfonylamino)-ethyl]-glycine derivatives having the formula II by hydrolysis, protection of secondary amine, cyclization, and deprotection of protecting group of secondary amine (FIG. 4). [00122]
[00123] (Formula Removed )
[00124] The entities represented by E, J, Rl, R2, R3, R4, R5, and HX may be as defined
above.
[00125] First, N-[2-(benzothiazole, benzoxazole, benzo[b]thiophene, or benzofuran-2-
sulfonylamino)-cthyl]-glycine derivatives having the formula II are converted to
corresponding acids by adding excess hydroxide ion source. Preferred R6 in the formula 11
is methyl or ethyl. Examples of hydroxide ion sources include, but are not limited to,
lithium hydroxide, sodium hydroxide, and potassium hydroxide. Preferred hydroxide ion
source is lithium hydroxide. The reaction mixture without work-up is then treated with a
protecting group such as di-t-butyl dicarbonate to protect secondary amine to obtain a
compound having the general formula:
[00126] (Formula Removed )
[00127] The entities represented by E, J, Rl, R2, R3, R4, and R5 are as defined above. [00128] Preferred hydrolysis reaction is carried out by adding an aqueous solution of lithium hydroxide (2 equivalent) to a solution of N-[2-(benzothiazole, benzoxazole, benzo[b]thiophene, or benzofuran-2-suIfonylamino)-ethyl]-glycine ester derivative at ambient temperature. After completion of the reaction by TLC analysis, an aqueous solution
of lithium hydroxide (additional 1 equivalent) is added to the reaction mixture. The reaction mixture is stirred for sufficient time. Then the excess di-t-butyl dicarbonate is removed by extraction with ethylacetate. The aqueous solution is then acidified, extracted with dichloromethane, dried, and evaporated in reduced pressure to yield a solid. Examples of solvents of above reaction are aqueous tetrahydrofuran, aqueous dioxane, and aqueous 1,2-dimethoxyethane. Preferred solvent is aqueous tetrahydrofuran.
(00129] Second, the cyclization reaction of carboxylic acids having general formula III
and followed by deprotection of t-Boc produces piperazinone derivatives having general
formula IV .The cyclization reaction occurs simultaneously during activation of carboxylic
acid. The activation of carboxylic acid can be conducted by general coupling reagent for
peptide synthesis at ambient temperature. Examples of coupling reagents include, but are
not limited to, HATU, HOAt, HODhbt (L. A. Carpino et al., J. Am. Chem. Soc, 1993, J15,
4397-4398), HAPyU, TAPipU (A. Ehrlich et al., Tetrahedron Lett., 1993, 4781-4784),
HBTU (V. Dourtoglou et al., Synthesis, 1984, 572-574), TBTU, TPTU, TSTU, TNTU (R.
Knorr et al., Tetrahedron Lett., 1989, 1927-1930), TOTU, BOP (B. Castro et al.,
Tetrahedron Lett., 1975, 1219-1222), PyBOP (J. Coste et al., Tetrahedron Lett., 1990, 205-
208), BroP (J. Coste et al., Tetrahedron Lett., 1990, 669-672), PyBroP (J. Coste et al.,
Tetrahedron Lett., 1991, 1967-1970), BOI (K.Akaji et al., Tetrahedron Lett., 1992, 3177-
3180), MSNT (B. Blankemeyer-Menge et al., Tetrahedron Lett.. 1990, 1701-1704), TDO
(R. Kirstgen et al., J. Chem. Soc, Chem. Commun., 1987, 1870-1871), DCC, EDCI, CDI
(H. A. Staab, Justus Liebigs Ann. Chem., 1957, 609, 75.), HOBt (W Konig et al., Chem.
Ber., 1970, 103, 788, 2024, 2034), HOSu (E. Wiinsch et al., Chem. Bet:. 1966, 99, 110),
NEPIS (R. B. Woodward et al.,. J. Am. Chem. Soc, 1961, 83, 1010), BBC (S. Chen et al.,
Tetrahedron Lett. 1992, 33, 647), BDMP (P, Li et al., Chem. Lett. 1999, 1163), BOMI (P,
Li et al., Tetrahedron Lett.. 1999, 40, 3605), AOP (L. A Carpino et al., Tetrahedron Lett.,
1994, 35, 2279), BDP (S. Kim et al., Tetrahedron Lett., 1985, 26, 1341), PyAOP (F.
Albericio et al., Tetrahedron Lett. 1997, 38, 4853), TDBTU (R. Knorr et al., Tetrahedron
Lett. 1989, 30, 1927), BEMT (P. Li et al., Tetrahedron Lett. 1999, 40, 8301), BOP-C1 (J.
Diago-Meseguer et al., Synthesis 1980, 547), BTFFH, TFFH (A. El-Faham et al.. Chem.
Lett.. 1998, 671), CIP (K. Akaji, et al., Tetrahedron Lett.. 1994, 35, 3315), DEPBT (H. Li et
al. Organic Lett. 1999, /, 91), Dpp-Cl (R. Ramage et al., J. Chem. Soc, Perkin Trans 1,
1985, 461), EEDQ (B Belleau et al., /. Am. Chem. Soc. 1968, 90, 1651), FDPP (S Chen et
al., Tetrahedron Lett. 1991, 32, 6711), HOTT, TOTT (M. A. Bailen et al., J. Org. Chem.
1999, 64, 8936), PyCloP (J. Coste et al., Tetrahedron Lett. 1991, 32, 1967 and J. Coste et
al., J. Org. Chem., 1994, 59, 2437). The solvents may be selected from tetrahydrofuran, dichloromethane, chloroform, DMF, and N-methylpyrrolidone. Preferred solvent is DMF. [00130| Alternatively, the activation of carboxylic acid can be conducted by formation of mixed anhydride using alkyl chlorotbrmate or alkanoyl chloride with non-nucleophilic organic base. Examples of alkyl halotbrmates or alkanoyl chlorides include, but are not limited to, methyl chloroformate, ethyl chloroformate, propyl chloroformate, butyl chloroformate, isobutyl chloroformate, pivaloyl chloride, and adamantine carboxyl chloride. The most preferred acid chloride is isobutyl chloroformate. The cyclization reaction using isobutyl chloroformate is carried out by slowly adding isobutyl chloroformate to a reaction solution of carboxylic acid having general formula III and non-nucleophilic organic base in an anhydrous appropriate solvent at the temperature between -30 °C and 10 °C. Examples of non-nucleophilic organic bases include, but are not limited to, triethylamine, tripropylamine, JV.N-diisopropylethylamine, N-methylmorphoIine, and N-ethylmorpholine. Preferred non-nucleophilic organic base is N-methylmorpholine. Examples of anhydrous appropriate solvents include, but are not limited to, acetonitrile, chloroform, dichloromethane, 1,2-dimethoxy ethane, diethyl ether, diisoproyl ether, and tetrahydrofuran. Preferred solvents are dichloromethane and tetrahydrofuran. The most preferred reaction temperature is in which the reaction mixture is allowed to slowly warm to 0 °C after completing addition of isobutyl chloroformate at -20 °C.
{00131] With reference to FIG. 4, the t-Boc group is deprotected in the presence of acid. Examples of acids include, but are not limited to, HC1, HBr, HF, HI, nitric acid, sulfuric acid, methanesulfonic acid, TFA, and trifluoromethanesulfonic acid. Preferred acid is TFA. The solvents used in the deprotection reaction may include without limitation dichloromethane, chloroform, carbon tetrachloride, ethyl acetate, toluene, and benzene. Preferred is dichloromethane. [001321 Synthesis of PNA Monomer
|00133| According to a method of this invention, PNA monomers having general formula I may be synthesized by at least two methods. With reference to FIG. 5, the first approach to PNA monomer syntheses is a method that introduces protected or unprotected nucleobase acetic acid moieties to protected linear backbone prior to cyclization reaction. Alternatively, PNA monomers may be synthesized by beginning with cyclization of protected linear backbone, followed by coupling of protected or unprotected nucleobase acetic acid moieties to create desired products. [00134] Method 1
[00135] The linear moieties having general formula V are prepared from protected linear backbone having general formula II by acylation of nucleobase acetic acid moieties using coupling reagents as shown in FIG. 5.
[00136] With reference to FIG. 5, the coupling reaction was conducted by addition of coupling reagent to the mixture of protected linear backbone having general formula II, nucleobase acetic acid moieties, and non-nucleophilic organic base in anhydrous appropriate solvent. Examples of coupling reagents include, but are not limited to, HATU, HOAt, HODhbt, HAPyU, TAPipU, HBTU, TBTU, TPTU, TSTU, TNTU, TOTU, BOP, PyBOP, BroP, PyBroP, BOl, MSNT, TDO, DCC, EDCI, CDI, HOBt, HOSu, NEP1S, BBC, BDMP, BOMI, AOP, BDP, PyAOP, TDBTU, BOP-C1, CIP, DEPBT, Dpp-Cl, EEDQ, FDPP, HOTT, TOTT, PyCloP. Preferred coupling reagent is PyBOP. Examples of non-nucleophilic organic bases include, but are not limited to, triethylamine, tripropylamine, N,N-diisopropylethylamine, N-methylmorpholine, and N-ethylmorpholine. Preferred non-nucleophilic organic base is N,N-diisopropylethylamine. Examples of anhydrous appropriate solvents include, but are not limited to, chloroform, dichloromethane, 1,2-dimethoxyethane, tetrahydrofuran, DMF, and N-methylpyrrolidone. Preferred solvent is DMF. [00137)
[00138] (Formula Removed )
[001391 The entities represented by E, J, Rl, R2, R3, R4, R5, R6, and B are as defined
above.
[00140] Compounds having the general formula V are converted to corresponding acids
such as formula VI by adding an excess of hydroxide ion source. Preferably, R6 may be a
methyl, ethyl or t-butyl. Examples of hydroxide ion sources include, but are not limited to,
lithium hydroxide, sodium hydroxide, and p otassium hydroxide. Preferred hydroxide ion
source is lithium hydroxide.
[00141]
100142] (Formula Removed )
[00143] The entities represented by E, J, Rl, R2, R3, R4, R5, and B are as defined above. [00144] Further, with reference to FIG. 5, the cyclization reaction of carboxylic acids produces PNA monomers having the general formula I by simultaneous reaction during activation of carboxylic acid. The activation of carboxylic acid may be conducted by general coupling reagent for peptide synthesis at ambient temperature. Examples of coupling reagents include, but are not limited to, HATU, HOAt, HODhbt, HAPyU, TAPipU, HBTU, TBTU, TPTU, TSTU, TNTU, TOTU, BOP, PyBOP, BroP, PyBroP, BOI, MSNT, TDO, DCC, EDCI, CDI, HOBt, HOSu, NEPIS, BBC, BDMP, BOMI, AOP, BDP, PyAOP, TDBTU, BOP-C1, CIP, DEPBT, Dpp-Cl, EEDQ, FDPP, HOTT, TOTT, PyCloP. Preferred coupling reagent is PyBOP. Examples of non-nucleophilic organic bases include, but are not limited to, triethylaminc, tripropylamine, N,N-diisopropylethylamine, N-methylniorpholine, and N-ethylmorpholine. Preferred non-nucleophilic organic base is N,N-diisopropylethylamine. The solvents may be without limitation selected from tetrahydrofuran, dichloromethane, chloroform, DMF, or N-methylpyrrolidone. Preferred solvent is DMF.
[00145] Alternatively, the activation of carboxylic acid can be conducted by formation of mixed anhydride using alkyl chloroformate or alkanoyl chloride with non-nucleophilic organic base. Examples of alkyl haloformates or alkanoyl chlorides include, but are not limited to, methyl chloroformate, ethyl chloroformate, propyl chloroformate, butyl chloroformate, isobutyl chloroformate, pivaloyl chloride, and adamantine carboxyl chloride. The most preferred acid chloride is isobutyl chloroformate. The cyclization reaction using isobutyl chloroformate is carried out by slowly adding isobutyl chloroformate to a reaction solution of carboxylic acid and non-nucleophilic organic base in an anhydrous appropriate solvent at a temperature between -30 °C and 10 °C. Examples of non-nucleophilic organic bases include, but are not limited to, triethylamine, tripropylamine, N,N-diisopropylethylamine,N-methylmorpholine, and N-ethylmorpholine. Preferred non-nucleophilic organic base is N-methylmorpholine. Examples of anhydrous appropriate solvents include, but.are not limited to, acetonitrile, chloroform, dichloromethane, 1,2-dimethoxyethane, diethyl ether, diisoproyl ether, and tetrahydrofuran. Preferred solvents are
dichloromethane and tetrahydroturan. Preferred reaction temperature is in which the
reaction mixture is allowed to slowly warm to about 0 °C after completing addition of
.isobutyl chloroformate at -20 °C.
|00146| Method 2
|00147) As an alternative method, PNA monomers according to this invention may be
prepared by coupling of protected or unprotected nucleobase acetic acid moieties to cyclic
precursor having the general formula IV:
[001481
|00149] (Formula Removed ) [00150]
[00151) The entities represented by E, J, Rl, R2, R3, R4, and R5 are as defined above. [00152] With reference to FIG. 6, the coupling reaction of cyclic precursor with protected or unprotected nucleobase acetic acid moieties is carried out by using general coupling reagent for peptide synthesis and non-nucleophilic organic bases at ambient temperature. Examples of coupling reagents include, but are not limited to, HATU, HOAt, HODhbt, HAPyU, TAPipU, HBTU, TBTU, TPTU, TSTU, TNTU, TOTU, BOP, PyBOP, BroP, PyBroP, BOl, MSNT, TDO, DCC, EDCI, CD!, HOBt, HOSu, NEPIS, BBC, BDMP, BOMI, AOP, BDP, PyAOP, TDBTU, BOP-C1, CIP, DEPBT, Dpp-Cl, EEDQ, FDPP, HOTT, TOTT, PyCloP. Preferred coupling reagent is PyBOP. Examples of non-nucleophilic organic bases include, but are not limited to, triethylamine, tripropylamine, iV.N-diisopropylethylamine, N-methylmorpholine, and N-ethylmorpholine. Preferred non-nucleophilic organic base is MiV-diisopropylethylamme. The solvent may be without limitation tetrahydrofuran, dichloromethane, chloroform, DMF, or N-methylpyrrolidone. Preferred solvent is DMF. [00153] Nucleobases and Protecting Group
[00154] Examples of nucleobases of this invention include, but are not limited to, adenine, cytosine, guanine, thymine, uridine, 2,6-diaminopurine, and naturally or non-
naturally occurring nucleobases as depicted in FIG. 1 and FIG. 2. Preferred nucleobases are adenine, cytosine, guanine, and thymine. Nucleobases may be protected by protecting group for the syntheses of PNA oligomers. Protecting groups may be, but are not limited to, Boc, adamantyloxycarbonyl, benzyloxycarbonyl (P. E. Nielsen et al., Science, 1991, 254, 1497-1500; M. Egholm et al., J. Am. Chem. Soc, 1992, 114, 9677-9679; M. Egholm et al.,./. Am. Chem. Soc, 1992,114, 1895-1897; M. Egholm etal.,7. Chem. Soc. Chem. Commun., 1993, 800-801; K. L. Ducholm et al., J. Org. Chem., 1994, 59, 5767-5773; WO 92/20702), 4-methoxybenzyloxycarbonyl, 3,4-dimethoyxbenzyloxycarbonyl, benzhydryloxycarbonyl (U. S. Patent No. 6,133,444), piperonyloxycarbonyl derivatives, 2-methylthioethoxycarbonyl (U. S. Patent No. 6,063,569), Mmt (G. Breipohl et al., Bioorg. Med. Chem. Lett., 1996, 6, 665-670), or acid labile protecting group (T. W. Greene and P. G. M. Wuts, Protective Group in Organic Synthesis, 3rd Edition, pp 494-653). |00155] Synthesis of T-Monomer
|00156] T-monomer is a compound having general formula I-t: |00157j
|00158|(Formula Removed )
100159]
|00160] The entities represented by E, J, Rl, R2, R3, R4, and R5 are as defined above.
Preferably E is nitrogen, and J is sulfur.
|00161] The precursor for T-monomer, (thymin-l-yl)-acetic acid (shown below), is
prepared by known methods (K. L. Dueholm et. al., /. Org. Chem., 1994, 59, 5767-5773;
WO 92/20702).
[00162|(Formula Removed )
(00163) With reference to FIG. 8, the compounds of general formula V-t are prepared by
coupling reaction of (thymin-l-yl)-acetic 3cid with benzothiazole-2-sulfonyl, benzoxazole-
2-sulfonyl, benzo[b]thiophene-2-sulfonyl or benzofuran-2-sulfonyl group protected
backbone ester having general formula II in the presence of coupling reagent to afford the
compound having general formula:
[00164] (Formula Removed )
[001651
[00166] The entities represented by E, J, Rl, R2, R3, R4, R5, and R6 are as defined
above. Preferably E is nitrogen, and J is sulfur.
[00167] Preferred R6 is methyl, ethyl or t-butyl.
[00168] The compounds having the general formula V-t are converted to corresponding
acids by adding an excess hydroxide ion source to afford the compound having.general
formula Vl-t.
[00169]
[00170] (Formula Removed )
[00171] The entities represented by E, J, Rl, R2, R3, R4, and R5 are as defined above.
Preferably E is nitrogen, and J is sulfur.

|00172| With reference to FIG. 8, the cyclization reaction of carboxylic acids produces
PNA T-monomers having general formula I-t by simultaneous reaction during activation of
carboxylic acid. The activation of carboxylic acid may be conducted by general coupling
reagent for peptide synthesis or mixed anhydride. The reaction conditions and reagents arc
the same as described above.
(00173] Alternatively, as seen in FIG. 9, PNA T-monomers can be prepared by coupling
(thymin-l-yl)-acetic acid to piperazinone derivatives having general formula IV. The
reaction conditions and reagents are the same as described above.
100174J Synthesis of C-Monomer
|00175) C- monomer is a compound having general formula I-c:
|00176] (Formula Removed )
100177]
[00178] The entities represented by E, J, Rl, R2, R3, R4, R5, and R7 are as defined
above. Preferably E is nitrogen, and J is sulfur.
[00179] The precursors for PNA C-monomers, suitably protected (cytosin-l-yl)-acctic
acids (shown below), are prepared by the method according to the scheme as depicted in
FIG. 7 and known methods such as described in U. S. Patent No. 6,133,444; U. S. Patent
No. 6,063,569; Dueholm, et al., J. Org. Chem., 1994, 59, 5767-5773; and WO 92/20702,
which are incorporated by reference herein in their entirety, or modifications thereof.
100180] (Formula Removed )
(00181] R7 may be methyl, ethyl, benzyl, benzhydryl, 4-methoxybenzyl, 3,4-
dimethoxybenzyl, piperonyl derivatives, or 2-methylthioethyl group.
|00182] With reference to FIG. 10, PNA C-monomer is prepared by coupling reaction of
suitably protected (cytosin-l-yl)-acetic acids with a benzothiazole-2-sulfonyl, benzoxazole-
2-sulfonyl, benzo[b]thiophene-2-sulfonyl or benzofuran-2-sulfonyl group protected
backbone ester having general formula II in the presence of coupling reagent to afford the
compound having general formula:
[00183] (Formula Removed )
(00184] The entities represented by E, J, Rl, R2, R3, R4, R5, R6, and R7 are as defined above. Preferably E is nitrogen, and J is sulfur.
(00185] The compounds having the general formula V-c are converted to corresponding acids by adding an excess of hydroxide ion source to obtain a compound having general formula VI-c:
(00186]
(Formula Removed ) [00187] The entities represented by E, J, Rl, R2, R3, R4, R5, and R7 are as defined
above. Preferably E is nitrogen, and J is sulfor.
[00188] With reference to FIG. 10, the cyclization reaction of carboxylic acids produces
PNA monomers having the general formula I-c by simultaneous reaction during activation
of carboxylic acid. The activation of carboxylic acid may be conducted by general coupling
reagent for peptide synthesis or mixed anhydride. The reaction conditions and reagents are
the same as described above.
[00189] Alternatively, as seen in FIG. 11, PNA C-monomer can be prepared by coupling
suitably protected (cytosin-l-yl)-acetic acids to piperazinone derivatives having general
formula IV. The reaction conditions and reagents are the same as described above.
[00190] Synthesis of A-monomer
[001911 A-monomer is a compound having general formula I-a:
[00192] (Formula Removed )
100193] The entities represented by E, J, Rl, R2, R3, R4, R5, and R7 are as defined
above. Preferably E is nitrogen, and J is sulfur.
|00194] The precursors for PNA A-monomers, suitably protected (adenin-9-yl)-acetic
acids (shown below), are prepared by the method according to the scheme as depicted in
FIG. 7 and known methods such as described in U. S. Patent No. 6,133,444; and S. A.
Thomson et al., Tetrahedron, 1995, 6179-6194, which are incorporated by reference herein
in their entirety, or modifications thereof.
[00195] (Formula Removed ) [00196] R7 is selected from methyl, ethyl, benzyl, benzhydryl, 4-methoxybenzyl, 3,4-
dimethoxybenzyl, piperonyl derivatives, and 2-methylthioethyl group.
[00197] With reference to FIG. 12, PNA C-monomer is prepared by coupling reaction of
suitably protected (adenin-9-yl)-acetic acids with a benzothiazole-2-sulfonyl, benzoxazole-
2-sulfonyl, benzo[b]thiophene-2-sulfonyl or benzofuran-2-sulfonyl group protected
backbone ester having general formula II in the presence of coupling reagent to obtain the
compound having general formula V-a:
[00198] (Formula Removed )
[00199] The entities represented by E, J, Rl, R2, R3, R4, R5, R6, and R7 are as defined
above. Preferably E is nitrogen, and J is sulfur.
[00200] The compounds having the general formula V-a are converted to corresponding
acids by adding an excess hydroxide ion source to afford the compound having general
formula Vl-a:
(00201] (Formula Removed )
[002021 The entities represented by E, J, Rl, R2, R3, R4, R5, and R7 are as defined
above. Preferably E is nitrogen, and J is sulfur.
[00203) With reference to FIG. 12, the cyclization reaction of carboxylic acids produces
PNA monomers having the general formula 1-a by simultaneous reaction during activation
of carboxylic acid. The activation of carboxylic acid can be conducted by general coupling
reagent for peptide synthesis or mixed anhydride. The reaction conditions and reagents are
the same as described above.
[00204] Alternatively, as seen in FIG. 13, PNA A-monomer can be prepared by coupling
suitably protected (adenin-9-yl)-acetic acids to piperazinone derivatives having general
formula IV. The reaction conditions and reagents are the same as described above.
[00205] Synthesis of G-monomer
[00206] G- monomer is a compound having general formula I-g:
[00207[(Formula Removed )

[00208] The entities represented by E, J, Rl, R2, R3, R4, R5, and R7 are as defined
above. Preferably E is nitrogen, and J is sulfur.
[00209] The precursors for PNA G-monomers, suitably protected (guanin-9-yl)-acetic
acids (shown below), are prepared by the method according to the scheme depicted in FIG.
7 and known methods such as described in U. S. Patent No. 6,172,226, or modifications
thereof.
[00210] (Formula Removed )
[00211] R7 may be methyl, ethyl, benzyl, benzhydryl, 4-mcthoxybenzyl, 3,4-dimethoxybenzyl, piperonyl derivatives, or 2-methylthioethyl group.
[00212] With reference to FIG. 14, PNA G-monomer is prepared by coupling reaction of suitably protected (guanin-9-yl)-acetic acids with a benzothiazole-2-sulfonyl, benzoxazole-2-sulfonyl, benzo[b]thiophene-2-sulfonyI or benzofuran-2-sulfonyl group protected backbone ester having general formula II in the presence of coupling reagent to afford the compound having general formula V-g:
1002131(Formula Removed )
|00214] The entities represented by E, J, Rl, R2, R3, R4, R5, R6, and R7 are as defined
above. Preferably E is nitrogen, and J is sulfur.
|00215] The compounds having the general formula V-g are converted to corresponding
acids by adding an excess hydroxide ion source to afford the compound having general
formula Vl-g:
[00216}(Formula Removed )
[00217] The entities represented by E, J, Rl, R2, R3, R4, R5, and R7 are as defined above. Preferably E is nitrogen, and J is sulfur.
(00218) With reference to FIG. 14, the cyclization reaction of carboxylic acids produces PNA monomers having the general formula I-g by simultaneous reaction during activation of carboxylic acid. The activation of carboxylic acid can be conducted by general coupling _ reagent for peptide synthesis or mixed anhydride. The reaction conditions and reagents are the same as described above.
[00219] Alternatively, as seen in FIG. 15, PNA G-monomer can be prepared by coupling suitably protected (guanin-9-yl)-acetic acids to piperazinone derivatives having general formula IV. The reaction conditions and reagents are the same as described above. [00220] Synthesis of PNA oligomers
(00221] Various combinatorial synthetic methods already reported in chemical literati/re are generally applicable to PNA oligomer synthesis using the monomers of this invention. These methods include, but are not limited to, solid phase synthesis and solution phase synthesis. After the PNA monomers have been synthesized in the manner described above, PNA oligomers are constructed by solid phase synthesis on a suitable support material such as, but not limited to, polystyrene, polyoxyethylene-modified polystyrene, such as , for example Tentagel* or Controlled Pore Glass, which is provided with anchoring group which latently contains cleavable amine functional group. In solid phase synthesis, the first PNA monomer of this invention is incorporated by coupling reaction to solid support. The next step is systematic elaboration of desired PNA oligomer sequence. This elaboration includes repeated deprotection/coupling/capping cycles. The backbone protecting group on the last coupled monomer, benzothiazole-2-sulfonyl, benzoxazole-2-sulfonyl,
benzo[b]thiophene-2-sulfonyl or benzofuran-2-sulfonyl group, is quantitatively removed by treatment with suitable thiol in the presence of organic base to liberate terminal free amine.
Once the synthesis of PNA oligomer has been completed, the oligomers are cleaved from
the solid support and nucleobase protecting groups are simultaneously removed by
incubation for 1-2 h. at about room temperature in TFA containing cresol as a cation
scavenger.
[00222] Following is an example of a general reaction cycle that may be used for the
synthesis of PNA oligomers, and is not meant to limit the invention in any way, such as in
the sequence of steps, since any oligomer synthesis method may be generally used so long
as the inventive PNA monomer is employed.
[00223] 1. Removing protecting group from resin to activate amine functional group.
[00224) 2. Incorporating amino-acid, linker, or PNA monomer having terminal
protected amine group to resin.
|00225| 3. Washing.
[00226] 4. Capping with acetic anhydride in the presence of organic base.
[00227] 5. Washing.
[00228] 6. Cleavage over reacted acetyl group in sulfonamide.
[00229] 7. Washing.
[00230] 8. Deprotectingsulfonyl group.
[00231] 9. Washing.
[00232] 10. Adding monomer.
[00233] 11. Returning to No. 3 and repeating No. 4 - No. 11.
[00234] In the course of the coupling reaction of monomer for the oligomer synthesis
reaction, the acylating reaction can be accelerated by using a catalyst such as but not limited
to mercury acetate, tetramethylammonium fluoride, tetraethylammonium fluoride,
tetrabutylammonium fluoride, benzyltrimethylammonium fluoride, cesium fluoride,
tributylphosphine, triphenylphosphine. Preferred catalyst is tetrabutylammonium fluoride.
Also, the reaction rate depends on the solvent used and reaction temperature. Examples of
solvents include, but are not limited to, DMF, N-methylpyrrolidone, dimethoxyethane,
dichloromethane, 1,2-dichloroethane, DMSO, tetrahydrofuran, hexamethylphophoramide,
tetramethylene sulfone, isopropyl alcohol, ethyl alcohol, and mixture of selected sovents.
Preferred solvent is DMF. The N-terminal amino protecting group is cleaved by using thiol
with organic base in solvent. Examples of thiols include, but are not limited to, C2--C20
alkanethiol, 4-methoxytoluenethiol, 4-methylbenzenethiol, 3,6-dioxa-l,8-octanethiol, 4-
chlorotoluenethiol, benzylmercaptane, N-acetylcysteine, N-(t-Boc)cysteine methyl ester,
methyl 3-mercaptopropionatc, 4-methoxybenzene thiol. Examples of organic bases include,
but are not limited to, triethylamine, N,N-diisopropyethylamine, piperidine, N-
methylmorpholine, and l,8-diazabicyclo[5,4,0]undec-7-one. Preferred organic base is N,N-
diisopropyethylamine.
[00235] List of abbreviations.
[00236] t-Boc tert-Butyloxycarbonyl
[00237] AOP O-(7-azabenzotriazol-l-yl)-tris(dimethylamino)phosphonium
[00238] BBC l-benzotriazol-l-yloxy-bis(pyrrolidino)uronium hexafluorophosphate
[00239] BDMP 5-(lN-benzotriazol-I-yloxy)-3,4-dihydro-l-methyl 2N-pyrrolium
hexachloroanitimonate
[00240] BDP benzotriazol-1-yl diethyl phosphate
[00241] BEMT 2-bromo-3-ethyl-4-methyl thiazolium tetrafluoroborate
[00242] BTFFH bis(tetramethylenefluoroformamidinium) hexafluorophosphate
|00243] BOMI benzotriazol-1-yloxy-N,N-dimethylmethaniminium
hexachloroantimdnate
[00244] BOI 2-(benzotriazol-l-yl)oxy-l,3-dimethyl-imidazolinium
hexafluorophosphate
|00245] BOP benzotriazolyl-l-oxy-tris(dimethylamino)phophonium
hexa fluorophosphate
|00246] BOP-C1 bis(2-oxo-3-oxazolidinyl)phosphintc chloride
[00247] BroP bromotris(dimethylamino)phophonium hexafluorophosphate
[00248] CDI carbonyldiimidazole
[00249] OP 2-chloro-l,3-dimethylirnidazolidinium hexafluorophosphate
[00250] DMF dimethylformamide
[00251] DCC 1,3-dicyclohexylcarbodiimide
[00252] DEPBT 3-(diethoxyphosphoryloxy)-l ,2>beiuotriazin-4(3fl)-one
[00253] Dpp-Cl diphenylphosphinic chloride
|00254] EDCI l-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride
|00255] EEDQ 2-ethoxy-l-ethoxycarbonyl-l,2-dihydroquinoline
(00256] Fmoc 9-fluorenylmethyloxycarbonyI
[00257] FDPP pentafluorophenyl diphenylphosphinate
[00258] HAPyU O-(7-azabenzotriazol-1 -yl)-1,1 3,3-bis(tetramethylene)urnium
hexafluorophosphate
[00259] HATU O-(7-azabenzotriazol-l-yl)-l,l,3,3-tetramethyluraniurn
hexafluorophosphate
[00260] HBTU O-(benzotriazol-l-y!)-l,l,3,3-tetramethyluranium
hexafluorophosphate
[00261] HOBt hydroxybenzotriazole
[00262] HO At l-hydroxy-7-azabenzotriazole
[00263] HODhbt 3-hydroxy-3,4-dihydro-4 oxo-l,2,3-benzotriazine
[00264] HOSu hydroxysuccinimide
[00265] HOTT S-(l-oxido-2-pyridinyl)-l,1,3,3-tetramethylthiouroniurn
hexafluorophosphate
[00266] MSNT 2,4,6-mesitylenesulfonyl-3-nitro-i,2,4-triazolide
[00267] Mmt 4-methoxyphenyldiphenylmethyl
[00268] NEPIS N-ethyl-5-phenyiisoxazolium-3'-sulfonate
[00269] PyAOP 7-azobenzotriazolyoxytris(pyrrolidino)phosphonium
hexafluorophosphate
[00270] PyBOP benzotriazolyl-l-oxy-tripyrrolidinophosphonium
hexafluorophosphate
[00271] PyBroP brornotripyrrolidinophosphonium hexafluorophosphate
[002721 PyCloP chlorotris(pyrrolydino)phophoniurn hexafluorophosphate
[00273] TAPipU 0-(7-azabenzotriazol-1 -yl)-1,1,3,3-bis(pentamethyIene)uranium
tetratluoroborate
[00274] TBTU 0-(benzotriazol-l-yl)-l,l,3,3-tetramethyluranium tetrafluoroborate
[00275] TDO 2,5-diphenyl-2,3-dihydro-3-oxo-4-hydroxythiophene dioxide
[00276] TFA trifluoroacetic acid
[00277] TFFH tetramethylfluoroformamidinium hexafluorophosphate
[002781 TOTT S-(l-oxido-2-pyridinyl)-l,l,3,3-tetramethylthiouronium
tetrafluoroborate
[00279] TDBTU 2-(3,4-dihydro-4-oxo-! ,2,3-benzotriazin-3-yl)-1,1,3,3-
tetramethyluronium
[00280] tetrafluoroborate
[00281] TNTU O-[(5-norbonene-2,3-dicarboximido)4,l,3,3-tetramethy\uronium
tetrafluoroborate
[00282] TOTU O-[(cyano(ethoxycarbonyl)methylene)amino]-l,l,3.3-
tetramethyluronium tetrafluoroborate
[00283] TPTU 0-( 1,2-dihydro-2-oxo-1 -pyridyl-1,1,3,3-tetramethyluronium
tetrafluoroborate
[00284] TSTU O-(N-succinimidyl)-l,l,3,3-tetramethyluronium tetrafluoroborate
|00285) This invention is more specifically illustrated by following Examples, which are
not meant limit the invention, unless otherwise noted.
EXAMPLES
[00286] EXAMPLE 1 - N-[2-{Benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl ester [00287] To a solution ofN-(2-aminoethyl)-glycine ethyl ester 2HC1 (1.10 g, 5.0 mmol), prepared as described by Will (D. W. Will et al., Tetrahedron, 1995, 51, 12069.), in dichloromethane (50 mL) was slowly added triethylamine (2.02 g, 20 mmol) at room temperature. Then benzothiazole-2-sulfonyl chloride (1.19 g 5.0 mmol) in dichloromethane (10 mL) was added to the reaction mixture at room temperature for 5 min. The resulting reaction mixture was stirred for additional 2 h. at room temperature and washed with water (30 mL). The organic layer was dried over MgSO4 and filtered. The filtrate was evaporated to remove solvent to give desired product (1.60 g, 92 %) as a solid. "H NMR (500 MHz ;
DMSO-d6) δ 8.28 (d, 1H), 8.19 (d, 1H), 7.69-7.63 (m, 2H), 4.03 (q, 2H), 3.24 (s, 2H), 3.13
(t, 2H), 2.62 (t, 2H), 1.15 (t, 3H).
[00288J EXAMPLE 2 - [2-(5-Chloro-benzothiazole-2-suIfonylamino)-ethyl]-glycine
ethyl ester
[00289] The title compound (657 nig, 87 %) was synthesized by the reaction of N-(2-
aminoethyl)-glycine ethyl ester 2HCI (398 mg, 2.0 mmol) with 5-chloro-benzothiazole-2-
sulfonyl chloride (536 mg, 2.0 mmol) as per the procedure of example 1. 1H NMR (500
MHz ; DMSO-d6) δ 8.32 (d, 1H), 8.31 (s, 1H), 7.71 (d, 1H), 4.02 (q, 2H), 3.25 (s, 2H), 3.14
(t,2H), 2.62 (t,2H), 1.15 (t,3H).
100290) EXAMPLE 3 - [2-(4-Chloro-5-methoxy benzothiazole-2-sulfonylamino)-ethyl]-
glycine ethyl ester
|002911 The title compound (726 mg, 89 %) was synthesized by the reaction of N-{2-
aminoethyl)-glycine ethyl ester 2HC1 (398 mg, 2.0 mmol) with 4-chloro-5-methoxy-
benzothiazole-2-sulfonyl chloride (596 mg, 2.0 mmol) as per the procedure of Example 1.
1H NMR (500MHz ; DMSO-d6) δ 8.18 (d, 1H), 7.57 (d, 1H), 4.00 (q, 2H), 3.97 (s, 3H),
3.22 (s, 2H), 3.14 (t, 2H), 2.62 (t, 2H), 1.13 (t, 3H).
[00292] EXAMPLE 4 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-alanine ethyl ester
[00293] N-(2-AminoethyI)-alanine ethylester 2HC1, prepared as described by Puschl (A.
Puschl et al., Tetrahedron, 1998, 39, 4707.), was reacted with benzothiazole-2-sulfonyl
chloride as per the procedure of Example 1 to give the title compound. 1H NMR (500 MHz ;
DMSO-d6) δ 8.27 (d, 1H), 8.18 (d, 1H), 7.69-7.62 (m, 2H), 4.01 (q, 2H), 3.17 (q, IH), 3.13
(t, 2H), 2.61 (m, 1H), 2.49 (m, 1H), 1.13 (t, 3H), 1.06 (d, 3H)..
[00294] EXAMPLE 5 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-(tert-
butoxycarbonyl)-glycine
[00295] To a solution of N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl ester
(6.87 g, 20 mmol) in tetrahydroiuran (50 mL) was added a solution of LiOH (1.64 g , 40
mmol) dissolved in water (30 mL). After stirring for 1 hour at room temperature, di-t-butyl
dicarbonate (6.55 g, 30 mmol) was added to the reaction mixture. The resulting reaction
mixture was stirred for 30 min. and then a solution of LiOH (0.82 g, 0.02 mol) in water (15
mL) was added. After completion of the reaction by TLC, the precipitate was removed by
filtration and tetrahydroiuran was removed in vacuo. The residual solution was washed with
ethyl ether (100 mL). The aqueous layer was acidified to pH 3 by adding 2N HC1 and
extracted with dichloromethane(100 mL). The organic layer was dried over MgSO4 and
filtered. The filtrate was concentrated in vacuo to afford the desired product (7.88 g, 95 %).
1H NMR (500 MHz ; DMSO-d5) δ 8.73 (d, 1H), 8.19 (dd, 1H), 7.71-7.63 (m, 2H), 3.84 (s,
1H), 3.79 (s, 1H), 3.30-3.22 (m, 4H), 1.34 (s, 4.5H), 1.28 (s, 4.5H).
(002961 EXAMPLE 6 - N-[2-(5-Chloro-benzothiazole-2-sulfonylamino)-ethyl]-N(tert-
butoxycarbonyl)-glycine
(00297] The title compound (607 mg, 90 %) was synthesized from N-[2-(5-chloro-
benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl ester (567 g, 1.5 mmol) as per the
procedure of Example 5. 1H NMR (500 MHz ; DMSO-d6) δ 8.80 (br, 1H), 8.33 (d, 1H),
8.32 (g, 1H), 7.72 (d, 1H), 3.84 (s, 1H), 3.80 (s, 1H), 3.29 (m, 2H), 3.23 (m, 2H), 1.35 (s,
4.5H), 1.28(s,4.5H).
(00298J EXAMPLE 7 - N-[2-(4-Chloro-5-methoxy-benzothiazole-2-sulfonylamino)-
ethyl]-N-(tert-butoxycarbonyl)-gIycine
(00299| The title compound (655 mg, 91 %) was synthesized from N-[2-(4-chloro-5-
methoxy-benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl ester (612 g, 1.5 mmol) as
per the procedure of Example 5. 1H NMR (500 MHz ; DMSO-d6) δ 8.83 (br, 1H), 8.20 (d,
1H), 7.58 (d, 1H), 3.98 (s, 3H), 3.83 (s, 1H), 3.79 (s, 1H), 3.32-3.23 (m, 4H), 1.34 (s, 4.5H),
1.25(s,4.5H).
(00300) EXAMPLE 8 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-(tert-
butoxycarbonyl)-alanine
(00301] The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-a!anine ethyl ester as per the procedure of Example 5. 1H NMR (500
MHz ; DMSO-dfi) δ 8.85 (brs, 1H), 8.28 (d, 1H), 8.18 (dd, 1H), 7.71-7.64 (m, 2H), 4.33 (q,
0.5H), 4.07 (q, 1H), 3.34-3.15 (m, 4H), 1.34 (s, 4.5H), 1.32 (s, 4.5H), 1.29 (d, 2H).
(00302) EXAMPLE 9 - l-(Benzothiazole-2-sulfonyl)-piperazin-2-one trifluoroacetic acid
salt
|00303| To a solution of N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-A^-(tert-
butoxycarbonyl)-glycine (8.30 g, 20 mmol) in dichloromethane (100 mL) was added
dicyclohexyl carbodiimide (5.16 g, 25 mmol). After stirring for 2 hours at room
temperature, the precipitate was removed by filtration. The filtrate was concentrated to
approximately 30 mL and cooled to 0 °C. To a cold solution was added trifluoroacetic acid
(20 mL). The mixture was stirred for 2 h at the same temperature and ethyl ether (100 mL)
was slowly added. The precipitate product was filtered off, washed with ethyl ether, and
dried in vacuo to afford white solid (6.58 g, 80 %). 1H NMR (500 MHz ; DMSO-d6) δ 8.36
(m, 1H), 8.25 (m, IH), 7.76-7.70 (m, 2H), 4.17 (t, 2H), 3.96 (s, 2H), 3.56 (t, 2H).
|00304] EXAMPLE 10 - l-(5-Chloro-benzothiazole-2-sulfonyl)-piperazin-2-one
trifluoroacctic acid salt
(00305) The title compound (342 mg, 78 %) was synthesized from N-[2-(5-chlofo-
benzothiazo!e-2-sulfonylamino)-cthyl]-N-(tert-butoxycarbonyl)-glycine (540 mg, 1.2 mmol)
as per the procedure of Example 9. 1H NMR (500 MHz ; DMSO-d6) δ 9.55 (br, 2H), 8.40 (d,
1H), 8.39 (d, 1H), 7.79 (dd, 1H), 4.16 (t, 2H), 3.97 (s, 2H), 3.57 (t, 2H).
[00306] EXAMPLE 11 - l-(4-Chloro-5-methoxy-benzothiazole-2-sulfonyl)-piperazin-2-
one trifluoroacetic acid salt
|00307] The title compound (389 mg, 82 %) was synthesized from N-[2-(4-chloro-5-
methoxy-benzothiazole-2-sulfonylamino)-ethyl]-N-(tert-butoxycarbonyl)-glycine (576 mg,
1.2 mmol) as per the procedure of Example 9. 1H NMR (500 MHz ; DMSO-d6) δ 8.28 (d,
1H), 7.68 (d, IH), 4.16 (dd, 2H), 3.99 (s, 3H), 3.96 (s, 2H), 3.56 (dd, 2H).
[00308] EXAMPLE 12 - l-(Benzothiazole-2-sulfonyl)-3-methyl-piperazin-2-one
trifluoroacetic acid salt
|00309| The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-N-(tert-butoxycarbonyl)-alanine as per the procedure of Example 9.
1H NMR (500 MHz ; DMSO-d6) δ 9.80 (brs, 2H), 8.35 (m, IH), 8.25 (m, IH), 7.75-7.70
(m, 2H), 4.31-4.25 (m, 2H), 4.17 (m, IH), 3.70 (m, IH), 3.55 (m, IH), 1.34 (d, 3H).
[00310] EXAMPLE 13 - [4-N-(Piperonyloxycarbonyl)-cytosin-l-yl]-acetic acid ethyl
ester
|003U] The reaction mixture of (cytosin-l-yl)-acetic acid (3.94 g, 20 mmol) and 1,1'-
carbonyldimidazole (4.86 g, 30 mmol) in DMF was stirred for 25 min. at 100 °C. Then,
piperonyl alcohol (6.08 g, 40 mmol) was added to the reaction mixture. The resulting
reaction mixture was allowed to cool to room temperature for 2 h. The solvent was removed
in vacuo and the residue was dissolved in ethyl acetate (100 mL). The solution was washed
with water (100 mL X 2), dried over MgSO4, and filtered. The filtrate was concentrated in
vacuo and treated with ethyl ether to afford white solid. The solid was filtered off and dried
in vacuo to give the desired product (7.20 g, 96 %). 1H NMR (500 MHz ; DMSO-d6) δ
10.77 (s, IH), 8.04 (d, IH), 7.04 (d, IH), 7.00 (s, IH), 6.92 (s, 2H), 6.02 (s, 2H), 5.09 (s,
2H), 4.61 (s, 2H), 4.15 (q, 2H), 1.19 (t, 3H).
[00312} EXAMPLE 14 - [6-N-(Piperonyloxycarbonyl)-adenin-9-yl]-acctic acid ethyl ester
[00313] The title compound (6.8 g, 85 %) was synthesized from (adenin-9-yl)-acetic acid ethyl ester (4.42 g, 20 mmol) as per the procedure of Example 13.1H NMR (500 MHz ; DMSO-d6) δ 10.65 (s, 1H), 8.62 (s, 1H), 8.44 (s, 1H), 7.05 (s, 1H), 6.95 (d, 1H), 6.92 (d'. 1H), 6.03 (s, 2H), 5.20 (s, 2H), 5.12 (s, 2H), 4.18 (q, 2H), 1.22 (t, 3H). [00314] EXAMPLE 15 - (2-Amino-6-iodopurin-9-yl)-acetic acid ethyl ester [003151 To a solution of 2-amino-6-iodo-purine (78.3 g, 0.3 mol) in DMF (1960 mL) was added ethyl bromoacetate (55.1 g, 0.33 mol) and potassium carbonate (82.9 g, 0.6 mol). The resulting reaction mixture was stirred for 12 h at room temperature. The reaction mixture was concentrated to small volume (about 150 mL) in vacuo and the residue was dissolved in water. The solid was filtered off, washed with water and ethyl ether, and dried in vacuo to give the titled compound (98.4 g, 95%). 1H NMR (500MHZ ; DMSO-d6) δ 8.06 (s, 1H), 6.90 (br.s, 2H), 4.94 (s, 2H), 4.17 (q, 2H), 1.22 (t, 3H).
[00316] EXAMPLE 16 - [2-(Piperonyloxycarbonyl)-amino-6-iodopurine-9-yl]-acetic acid ethyl ester
[00317J To a solution of (2-amino-6-iodopurine-9-yl)-acetic acid ethyl ester (3.47 g, 10 mmol) in tetrahydrofuran (40 mL) was added triphosgene (1.20 g, 4 mmol) at 0 °C. After stirring for additional 30 min, JV.Af-diisopropylethylamine (3.30 g) was slowly added and the reaction mixture was stirred for 30 min at 0 °C. Then, piperonyl alcohol (2.30 g, 15 mmol) was added and the resulting reaction mixture was allowed to warm to room temperature and stirred for additional 1.5 h. To the resulting mixture was added water (50 mL) and ethyl alcohol (50 mL). The solution was concentrated to about 100 mL to precipitate solid. The solid was filtered off, washed with ethyl alcohol, and dried in vacuo to give the desired product (2.40 g, 46 %). 1H NMR (500 MHz ; DMSO-d6) δ 10.77 (s, 0.5H), 10.69 (s, 0.5H), 8.49 (s, 0.5H), 8.45 (s, 0.5H), 7.01 (s, 1H), 6.94 (d, 1H), 6.91 (d, 1H), 6.02 (s, 2H), 5.11 (s, 1H), 5.07 (s,2H), 5.06 (s, 1H).
[00318] EXAMPLE 17 - [4-N-(Piperonyloxycarbonyl)-cytosin-l-yl]-acetic acid [00319] To a suspension of [4-N-(piperonyloxycarbonyl)-cytosin-l-yl]-acetic acid ethyl ester (6.40 g, 17 mmol) in tetrahydrofuran (30 mL) and water (60 mL) was added lithium hydroxide monohydrate (1.6 g) at room temperature. After stirring 20 min, the reaction mixture was acidified by adding 1 N HC1 (40 mL). The precipitated solid was filtered off, washed with water (20 mL) and ethyl alcohol (20 mL), and dried in vacuo to give the
desired product (5.8 g, 98 %). 1H NMR (500 MHz ; DMSO-d6) δ 7.94 (d, 1H), 6.93 (d, 1H), 6.90 (s, 1H), 6.82 (s, 2H), 5.93 (s, 2H). 4.99 (s, 2H), 4.43 (s, 2H). [00320] EXAMPLE 18 - [6-N-(Piperonyloxycarbonyl)-adenin-9-yl]-acetic acid [00321] The title compound (3.67 g, 99 %) was synthesized from [6-N-(piperonyloxycarbonyl)-adenin-9-yl]-acetic acid ethyl ester (4.00 g, 10 mmol) as per the-procedure of Example 17. 1H NMR (500 MHz ; DMSO-d6) δ 10.53 (s, 1H), 8.52 (s, 1H), 8.33 (s, 1H), 6.96 (s, 1H), 6.86 (d, 1H), 6.82 (d, 1H), 5.93 (s, 2H), 5.02 (s, 2H), 4.99 (s, 2H). [003221 EXAMPLE 19 - [2-N-(Piperonyloxycarbonyl)-guanin-9-yl]-acetic acid [00323] To a suspension of 60% NaH (1.3 g, 32.5 mmol) in tetrahydrofuran (40 mL) was slowly added 3-hydroxypropionitrile (2.3 g, 29.5 mmol) for a period of 20 min. at 0 °C and the mixture was .vtirred for additional 30 nun. To the resulting reaction mixture was slowly added [2-(piperonyloxycarbonyl)-amino-6-iodo-purine-9-yl]-acetic acid ethyl ester (2.4 g, 4.6 mmol) portion-wise in an ice bath. After the addition was completed, the ice bath was removed and stirring continued for additional 3 h. Then, water (20 mL) was added and stirred for additional 30 min. The reaction mixture was acidified to pH 3 by addition of 1 N HCl solution. After removal of tetrahydrofuran in vacuo, the solution was cooled in ice bath and the solid collected by filtration. The solid was washed with water (20 mL) and ethyl alcohol (20 mL) and dried in vacuo to give the desired product (1.4 g, 84 %). 1H NMR (500 MHz ; DMSO-d6) δ 7.73 (s, 1H), 6.91 (s, !H), 6.84 (d, 1H), 6.82 (d, 1H), 5.93 (s, 2H), 5.04 (s, 2H), 4.39 (s, 2H).
[00324] EXAMPLE 20 -N-[2-(Benzotfuazole-2-sulfonylamino)-ethyl]-N-[(thymin-1 -yl)-acetylj-glycine ethyl ester
[00325] To the mixture of N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl ester (1.72g, 5 mmol), (thymin-l-yl)-acetic acid (0.92 g, 5 mmol), HOBt (0.81 g, 6 mmol), and DCC (1.24 g, 6 mmol) in DMF (15 mL) was added N,/V-diisopropylethylamine (1.31 mL, 7.5 mmol) at ambient temperature. The resulting reaction mixture was stirred for 5 h at the same temperature and the solvent was removed in vacuo to 5 mL. The residue was dissolved in dichloromethane (50 mL) and the precipitate was filtered. The filtrate was washed with IN HCl aqueous solution, satuiated sodium bicarbonate solution, and brine. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated and the residue was triturated with ethyl alcohol. The resulting solid was filtered off and dried in vacuo to give the title compound (1.91 g, 75 %) as a white solid. 1H
NMR (500 MHz; DMSO-d6) δ 11.29 (s, 0.6H), 11.28(s, 0.4H), 8.99(brs, 0.6H), 8.82(brs,
0.4H), 8.28(m, 1H) δ.18(d, 1H) 7.66-(m, 2H) 7.3l(s, 0.6H) 7.42(s, 0.4H) 4.66(s, 1.2H) 4.47(s, 0.8H) 4.3 l(s, 0.8H), 4.05(s. 1.2H), 4.04(q, 1.2H), 3.55(t, 1.2H), 3.40~3.34(m, 2.8H), 3.20(t, 0.8H), 1.73(s,3H), 1.19(t, 1.2H), 1.14(t, 1.8H).
1003261 EXAMPLE 21 - N-[2-(Benzothiazole-2-suIfonylamino)-ethyl]-N-{[4-N-(benzhydryloxycarbonyl)-cytosin-l-yl]-acctyl}-glycine ethyl ester
[00327] The title compound (2.99 g. 85 %) was synthesized by the reaction of N-{2-(benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl ester (1.72g, 5 mmol) and [4-N-(benzhydryloxycarbonyl)-cytosin-l-yl]-acetic acid (1.90 g, 5 mmol) as per the procedure of Example 20. 1H NMR (500 MHz; DMSO-d6) δ 11.00 (s, 1H), 8.86 (brs, IH), 8.27 (d, IH), 8.18 (d, IH), 7.89 (d, 0.6H), 7.83 (d, 0.4H), 7.68-7.61 (m, 2H), 7.45-7.26 (m, I OH), 6.94 (t, IH), 6.79 (s, IH), 4.81 (s, 1.2H). 4.62 (s, 0.8H), 4.35 (s, 0.8H), 4.13 (q, 0.8H), 4.06 (s. 1.2H), 4.03 (q, 1.2H), 3.59 (t, 1.2H). 3.44-3.39 (m, 2H), 3.21 (t, 0.8H), 1.19 (t, I.2H), 1.13 (t, 1.8H).
100328) EXAMPLE 22 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[4-N-(4-methoxybenzyloxycarbony!)-cytosin-1 -yl]-acetyl}-glycine ethyl ester |003291 The title compound (2.86 g, 87 %) was synthesized by the reaction of N-[2-(benzothiazole-2-sulfonylamino)-ethvl]-glycine ethyl ester (1.72g, 5 mmol) and [4-N-(4--. methoxybenzyloxycarbonyl)-cytosin-l-yll-acetic acid (1.67 g, 5 mmol) as per the procedure of Example 20. 'HNMR (500 MHz; DMSO-d6) δ 10.71 (s, IH). 8.26 (dd, IH), 8.16 (dd, IH), 7.90 (d, 0.6H), 7.82 (d, 0.4H), 7.68-7.60 (m, 2H), 7.34 (d, 2H), 7.00 (t, IH), 6.93 ,'d, 2H), 5.10 (s, 2H), 4.82 (s, 1.2H), 4.6: (s, 0.8H), 4.34 (s, 0.8H), 4.13 (q, 0.8H), 4.05 (s, 1.2H), 4.03 (q, 1.2H), 3.74 (s, 3H), 3.56 (t, 1.2H), 3.40-3.30 (m, 2H), 3.19 (t, 0.8H), 1.19 it, 12H), 1.12 (t, 1.8H).
[00330J EXAMPLE 23 - Aq2-(Benzothiazole-2-sulfonyIamino)-ethyl]-N-{[4-N-(3,4-dimethoxybcnzyIoxycarbonyl)-cytosin-l-yl]-acetyl}-glycine ethyl ester [003311 The title compound (5.31 g, 81 %) was synthesized by the reaction of N-[2-(benzothiazole-2-suIfonylamino)-ethyl]-glycine ethyl ester (3.26 g, 9.5 mmol) and [4-N-(3,4-dimethoxybenzyloxycarbonyl)-cytosin-l-yl]-acetic acid (3.28 g, 9.03 mmol) as per the procedure of Example 20. 1H NMR (500 MHz; DMSO-d6) δ 10.72 (s, IH), 8.27 (dd, IH), 8.17 (dd, IH), 7.90 (d, 0.6H), 7.82 (d. 0.4H), 7.69-7.62 (m, 2H), 7.02 (s, IH), 7.00 (t, IH), 6.94 (s, 2H), 5.09 (s, 2H), 4.80 (s, 1.2H), 4.61 (s, 0.8H), 4.34 (s, 0.8H), 4.13 (q, 0.8H), 4.05 (s, 1.2H), 4.03 (q, 1.2H), 3.75 (s, 3H), 3.74 (s, 3H), 3.58 (t, 1.2H), 3.42-3.37 (m, 2H), 3.20 (t,0.8H), 1.20 (t, 1.2H), 1.14 (t, 1.8H).
[00332] EXAMPLE 24 - N-[2-(Benzothiazole-2-sulfonylamino)-cthyl]-N-{[4-N-
(piperonyloxycarbonyl)-cytosin-1 -yl]-acetyl}-glycine ethyl ester
[00333] The title compound (2.89 g. 86 %) was synthesized by the reaction ofN-[2-
(benzothiazole-2-sulfonylamino)-clhyl]-gIycinc ethyl ester (1.72g, 5 mmol) and [4-N-
(piperonyloxycarbonyl)-cytosin-I-yl]-acetic acid (1.74 g, 5 mmol) as per the procedure of
Example 20. 1H NMR (500 MHz; DMSO-d6) δ 10.65 (s, 1H), 8.80 (brs, 0.6H), 8.68 (brs,
0.4H), 8.19(d, 1H), 8.11 (d, 1H), 7.81 (d, 0.6H), 7.75 (d, 0.4H), 7.62-7.54 (m, 2H), 6.92 (t,
1H), 6.90 (s, 1H), 6.82 (s, 211), 5.93 (s, 2H), 5.00 (s, 2H), 4.72 (s, 1.2H), 4.54 (s, 0.8H), 4.26
(s, 0.8H), 4.01 (q, 0.8H), 4.00 (s, 1.2H), 4.96 (q, 1.2H), 3.51 (t, 1.2H), 3.35-3.30 (m, 2H),
3.l3(t,0.8H), 1.12 (t, 1.2H), 1.06 (t, l.SH).
[003341
[00335) EXAMPLE 25 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[4-N-(2-
methylthioethoxycarbonyl)-cytosin-1 -yl]-acetyl}-glycine ethyl ester
[00336] The title compound (2.60 g, 85 %) was synthesized by the reaction of N-[2-
(benzothiazole-2-sulfonylamino)-ethyI]-glycine ethyl ester (1.72g, 5 mmol) and [4-N-(2-
methylthioethoxycarbonyl)-cytosin-1 -yl]-acetic acid (1.44g, 5 mmol) as per the procedure
of Example 20. 1H NMR (500 MHz; DMSO-d6) δ 8.89 (t, 0.6H) δ.75 (t, 0,4H) δ.28 (dd, 1H)
8.19(dd, 1H) 7.90 (d, 0.6H) 7.84 (d, 0.4H) 7.67 (m, 2H) δ.99 (m, 1H)4.81 (s, 1.2H)4.62(s,
0.8H) 4.35 (s, 0.8H) 4.26 (t, 2H) 4.14 (q, 0.8H) 4.06 (s, 1.2H) 4.04 (q, 1.2H) 3.59 (t, 1.2H)
3.42 (m, 2.0H) 3.21 (q, 0.8H) 2.73 (t, 2H) 2.12 (s, 3H) 1.20 (t, 1.2H) 1.15 (t, 1.8H).
[00337] EXAMPLE 26 - Aq2-(BenzothiazoIe-2-sulfonylamino)-ethyl]-N-{[6-N-
(benzhydryloxycarbonyl)-adcnin-9-yl]-acetyl} -glycine ethyl ester
[00338] The title compound (2.91 g, 80 %) was synthesized by the reaction of N-[2-
(benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl ester (1.72g, 5 mmol) and [6-N-
(benzhydryloxycarbonyl)-adenin-9-yl]-acetic acid (2.02 g, 5 mmol) as per the procedure of
Example 20. 1H NMR (500 MHz; DMSO-d6) δ 10.93 (s, 1H), 9.00 (s, 0.6H), 8.60 (s, 0.4H),
8.59 (s, 0.4H), 8.54 (s, 0.6H), 8.33(d, 1H), 8.28 (in, 1H), 8.19 (d, 1H), 7.69 (m, 2H), 7.52-
7.29 (m, 10H), 6.83 (s, 1H), 5.47 (s, 1.2H), 5.37 (s, 0.8H), 4.47 (s, 0.8H), 4.18 (q, 0.8H),
4.08 (s, 1.2H), 4.03 (q, 1.2H), 3.71 (t, 1.2H), 3.61 (q, 1.2H) 3.49 (t, 0.8H) 3.42 (q, 0.8H),
1.24 (t, 1.2H), l.I3(t, 1.8H).
[00339] EXAMPLE 27 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[6-N-(4-
methoxybenzyloxycarbonyl)-adenin-9-yl]-acetyl}-glycine ethyl ester
[00340] To the mixture of N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl
ester (172mg, 0.5mmol), [6-N-(4-methoxybenzyloxycarbonyl)-adenin-9-yl]-acetic acid
(179mg, 0.5mmol), and HBTU (190mg. 0.5mmol) in DMF (2ml) was added diisopropylethylamine (0.09ml, 0.5mmol) at ambient temperature. The resulting reaction mixture was stirred for 2h at the same temperature and IN HC1 was added to the reaction mixture. The resulting precipitate product was filtered off, washed with water, and dried in vacuo to give the title compound as a w Elite solid (0.35g, 97%). 1H NMR (500 MHz;. DMSO-d6) δ 8.97 (t, 0.6H) δ.76 (t. 0.4H) δ.64 (s, 0.4H) δ.60 (s, 0.6H) δ.53 (d, 1H) δ.28 (m, 1H) δ.17 (d, 1H) 7.66 (m, 2H) 7.40 (d, 2H) δ.95 (d, 2H) δ.41 (s, 1.2H), 5.20 (s, 0.8H) δ.18 (s, 2H) 4.46 (s, 0.8H) 4.18 (q, 0.8H) 4.08 (s, 1.2H) 4.03 (q, 1.2H) 3.75 (s, 3H) 3.70 (q, 1.2H)3.48(q, 1.2H) 3.42 (t, 0.8H) 3.22 (q. 0.8H) 1.24 (t, I.2H) 1.13 (t, 1.8H) [003411 EXAMPLE 28 - N-[2-(Benzothiazole-2-sulfonyIamino)-ethyl]-N-{[6-N-(3,4-dimethoxybenzyloxycarbonyl)-adenin-9-yl]-acetyl}-glycine ethyl ester 100342] The title compound (6.28 g, 96 %) was synthesized by the reaction of N-[2-(benzothiazolc-2-sulfonylamino)-ethyl]-glycine ethyl ester (3.26 g, 9.5 mmol) and [6-N-(3,4-dimethoxybenzyloxycarbonyl)-adenin-9-yl]-acetic acid (3.50 g, 9.03 mmol) as per the procedure of Example 27. 1H NMR (500 MHz; DMSO-d6) δ 10.58 (s, 1H), 8.98 (brs, 0.6H), 8.77 (brs, 0.4H), 8.57 (s, 0.4H), 8.53 (s, 0.6H), 8.29 (d, 1H), 8.27 (m, 1H), 8.17 (d, 1H), 7.65 (m, 2H), 7.08 (s, 1H), 6.98 (d, 1H), 6.94 (d, IH), 5.35 (s, 1.2H), 5.15 (s, 0.8H), 5.12 (s, 2H), 4.45 (s,0.8H), 4.18 (q, 0.8H). 4.07 (s, 1.2H), 4.01 (q, 1.2H), 3.75 (s, 3H), 3.74 (s, 3H), 3.70 (t, 1.2H),3.48(t, 1.2H), 3.42 (t, 0.8H), 3.22 (t, 0.8H), 1.23 (t, 1.2H), 1.12 (t, 1.8H). [00343] EXAMPLE 29 -N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[6-^-(piperonyloxycarbonyl)-adenin-9-yl]-acetyl}-glycine ethyl ester
[00344| The title compound (2.96g, 85 %) was synthesized by the reaction of N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl ester (1.72g, 5 mmol) and [6-N-(piperonyloxycarbonyl)-adenin-9-yl]-acetic acid (1.86 g, 5 mmol) as per the procedure of Example 20. 1H NMR (500 MHz; DMSO-d6) δ 10.63 (s, IH), 8.98 (brs, 0.6H), 8.77 (brs, 0.4H), 8.57 (s, 0.4H), 8.52 (s, 0.6H), 8.29 (d, IH), 8.27 (m, IH), 8.17 (d, IH), 7.65 (m, 2H), 7.04 (s, IH), 6.94 (d, IH), 6.90 (d, IH), 6.01 (s, 2H), 5.36 (s, 1.2H), 5.15 (s, 0.8H), 5.10 (s, 2H), 4.45 (s, 0.8H), 4.17 (q, 0.8H), 4.07 (s, 1.2H), 4.01 (q, 1.2H), 3.70 (t, 1.2H), 3.48 (t, 1.2H), 3.41 (t,0.8H), 3.22 (L0.8H), 1.23 (t, 1.2H), 1.12 (t, 1.8H).
[00345| EXAMPLE 30 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-^-{[6-N-(2-methylthioethoxycarbonyl)-adenin-9-yl]-acetyl}-glycine ethyl ester [00346] The title compound (2.77 g, 85 %) was synthesized by the reaction of N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl ester (1.72g, 5 mmol) and [6-N-(2-methylthioethoxycarbonyl)-adenin-9-yl]-acetic acid (1.56 g, 5 mmol) as per the procedure
of Example 20. 1H NMR (500 MHz; DMSO-d6) δ 10.59 (s, 1H), 8.97 (brs, 0.6H), 8.76 (brs, 0.4H), 8.57 (s, 0.4H), 8.52 (s, 0.6H), 8.28 (d, 1H), 8.17 (d, 1H), 7.65 (m, 2H), 5.35 (s, 1.2H), 5.14 (s, 0.8H), 4.46 (s, 0.8H), 4.17 (q. 0.8H), 4.06 (s, 1.2H), 4.02 (q, 1.2H), 3.70 (t, 1.2H), 3.47 (t, 1.2H), 3.42 (t, 0.8H), 3.21 (t, O.SH), 2.12 (s, 3H), 1.23 (t, 1.2H), 1.12 (t, 1.8H). [00347) EXAMPLE 31 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[2-N-(benzhydryloxycarbonyl)-guanin-9-yl]-acctyl}-glycine ethyl ester
[00348| The title compound (2.61 g, 70 %) was synthesized by the reaction of N-[2-(benzothiazolc-2-sulfonylamino)-ethyl]-glycine ethyl ester (1.72g, 5 mmol) and [2-N-(benzhydryloxycarbonyl)-guanin-9-yl]-acetic acid (2.10 g, 5 mmol) as per the procedure of Example 20. 1H NMR (500 MHz; DMSO-d6) δ 11.63 (bs, 1H), 11.23 (bs, 1H). 8.27 (d, 1H), 8.17 (t, 1H), 7.80 (s, 0.6H), 7.76 (s, 0.4H), 7.65 (m, 2H), 7.50-7.25 (m, 10H), 6.86 (s, 1H), 5.12 (s, 1.2H), 4.93 (s, O.SH), 4.44 (s, 0.8H), 4.18 (q, 0.8H), 4.08 (s, 1.2H), 4.04 (q, 1.2H), 3.65 (t, 1.2H),3.45(t, 1.2H),3.41 (t, O.SH), 3.21 (t, 0.8H), 1.23 (t, 1.2H), 1.17 (t, 1.8H). [00349J EXAMPLE 32 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[2-^-(4-methoxybenzyloxycarbonyl)-guanin-9-yl]-acetyl} -glycine ethyl ester [00350) The title compound (2.72 g, 78 %) was synthesized by the reaction of N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl ester (1.72g, 5 mmol) and [2-N-(4-methoxybenzyloxycarbonyl)-guanin-9-yl]-acetic acid (1.89 g, 5 mmol) as per the procedure of Example 20. 1H NMR (500 MHz; DMSO-d6) δ 8.26 (dd, 1H), 8.15 (dd, 1H), 7.80 (s, 0.6H), 7.76 (s, 0.4H), 7.65 (m, 2H), 7.36 (d, 2H), 6.94 (d, 2H), 5.16 (s, 2H), 5.09 (s, 1.2H), 4.90 (s, 0.8H), 4.42 (s, O.SH), 4.16 (q, 0.8H), 4.06 (s, 1.2H), 4.03 (q, 1.2H), 3.75 (s, 3H), 3.63(t, 1.2H), 3.43 (t, 1.2H), 3.39 (t, 0.8H), 3.20 (t, 0.8H), 1.21 (t, 1.2H), 1.12 (t, 1.8H). [003511 EXAMPLE 33 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[2-N-(3,4-dimethoxybenzyloxycarbonyl)-guanin-9-yl]-acetyl}-glycine ethyl ester [00352J The title compound (2.48 g, 68 %) was synthesized by the reaction of N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl ester (1.72g, 5 mmol) and [2-N-(3,4-dimethoxybcnzyloxycarbonyl)-guanin-9-yl]-acetic acid (2.02 g, 5 mmol) as per the procedure of Example 20. 1H NMR (500 MHz; DMSO-d6) δ 8.26 (dd, 1H), 8.14 (dd, 1H), 7.80 (s, 0.6H), 7.76 (s, 0.4H), 7.65 (m? 2H), 7.04 (s, 1H), 6.95 (m, 2H), 5.15 (s, 2H), 5.09 (s, 1.2H), 4.90 (s, 0.8H), 4.42 (s, 0.8H), 4.16 (q, 0.8H), 4.06 (s, 1.2H), 4.03 (q, 1.2H), 3.74 (s, 3H), 3.73 (s, 3H), 3.62 (t, 1.2H), 3.43 (t, 1.2H), 3.39 (t, 0.8H), 3.20 (t, 0.8H), 1.21 (t, 1.2H), 1.13 (t, 1.8H).
[00353] EXAMPLE 34 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[2-N-(piperonylyloxycarbonyl)-guanin-9-yl]-acetyl}-glycine ethyl ester
[00354] The title compound (2.71 g. 76 %) was synthesized by the reaction of N-[2-
(benzothiazole-2-sulfonylamino)-cthyl]-glycine ethyl ester (172g, 5 mmol) and [2-N-
(piperonyloxycarbonyl)-guanin-9-yl]-acetic acid (1.94 g, 5 mmol) as per the procedure of
Example 20. 1H NMR (500 MHz; DMSO-d6) δ 8.27 (d, 1H), 8.15 (dd, 1H), 7.80 (s, 0.6H},
7.76 (s, 0.4H), 7.65 (m, 2H), 7.01 (s, 1H), 6.95 (s, 2H), 6.01 (s, 2H), 5.13 (s, 2H), 5.10 (s,
1.2H), 4.91 (s, 0.8H), 4.43 (s, 0.8H), 4.16 (q, 0.8H), 4.06 (s, 1.2H), 4.03 (q, 1.2H), 3.62 (t,
1.2H), 3.43(t, 1.2H),3.39(t,0.8H),3.19(t,0.8H), 1.21 (t, 1.2H), 1.13 (t, 1.8H).
|00355| EXAMPLE 35 - N-[2-(Bcnzothiazole-2-sulfonylamino)-ethyl]-N-{[2-N-(2-
methylthioethoxycarbonyl)-guanin-9-yl]-acetyl}-glycine ethyl ester
[00356) The title compound (2.67 g, 75 %) was synthesized by the reaction of N-[2-
(benzothiazole-2-sulfonylamino)-ethyl]-glycine ethyl ester (1.72g, 5 mmol) and [2-N-{2-
methylthioethoxycarbonyl)-guanin-9-yl]-acetic acid (1.64 g, 5 mmol) as per the procedure
of Example 20.
[00357] EXAMPLE 36 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-[(thymin-l-yl)-
acetyl]-glycine
[00358] N-[2-(Benzothiazoie-2-sulfonylamino)-ethyl]-N-[(thymin-1 -yl)-acetyl]-glycine
ethyl ester (5.10 g, 10 mmol) was cuspended in tetrahydrofuran (20 tnL) and the solution of
lithium hydroxide monohydrate (1.03 g, 25 mmol) in water (20 mL) was added. The
reaction mixture was stirred for 1 h. at ambient temperature. The aqueous solution was
acidified by the dropwise addition of IN HC1 at 0 °C. The title compound was extracted
with ethyl acetate (3X10 mL), the combined extracts were dried over magnesium sulfate
and filtered. The filtrate was evaporated to dryness in vacuo to afford the desired product
(4.57 g, 95 %). 1H NMR (500 MHz; DMSO-d6) δ 11.30 (s, 0.6H), 11.28 (s, 0.4H), 8.88 (s,
0.6H), 8.77 (s, 0.4H), 8.27 (d, 1H), 8.18 (d, 1H), 7.69-7.64 (m, 2H), 7.31 (s, 0.6H), 7.23 (s,
0.4H), 4.64 (s. 1.2H), 4.45 (s, 0.8H), 4.21 (s, 0.8H), 3.98 (s, 1.2H), 3.52 (t, 1.2H), 3.38 (s,
2H), 3.21 (t,0.8H), 1.73 (s,3H).
[00359J EXAMPLE 37 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl)-N-{[4-N-
(benzhydryloxycarbonyl)-cytosin-1 -yl]-acetyl} -glycine
[00360| The title compound (629 mg, 93 %) was synthesized fromN-[2-(benzothiazole-
2-sulfonylamino)-ethyl]-N-{[4-N'-(benzhydryloxycarbonyl)-cytosin-l-yI]-acetyl}-glycine
ethyl ester (705 mg, 1.0 mmol) as per the procedure of Example 36. !H NMR (500 MHz;
DMSO-df,) δ 11.00 (brs 1H), 8.90 (brs, 1H), 8.26(dd, 1H), 8.18 (d, 1H), 7.90 (d, 0.6H), 7.82
(d, 0.4H), 7.68-7.61 (m, 2H), 7.45-7.62 (m, 10H), 6.94 (dd, 1H), 6.79 (s, IH), 4.80(s, 1.2H),
4.60 (s,0.8H), 4.20 (s, 0.8H), 3.99 (s, 1.2H), 3.56 (t, 1.2H), 3.39(m, 2H), 3.21 (t, 0.8H).
(00361) EXAMPLE 38 - N-[2-(Benzothiazole-2-sulfonylamino)-et!\yl]-N-{l4-N-(4-
methoxybenzy loxycarbonyl)-cytosin-1 -yl]-acelyl} -glycine
|00362] The title compound (605 mg. 96 %) was synthesized from N-[2-(benzothiazole-
2-sulfonylamino)-cthyl]-N-{[4-N-(4-methoxybenzyloxycarbonyl)-cytosin-l-yl]-acetyl}- .
glycine ethyl ester (658 mg, 1.0 mmol) as per the procedure of Example 36. 1H NMR (500
MHz; DMSO-d6) δ 10.75 (bs, 1H), 8.89 (t, 0.6H), 8.76 (t, 0.4H), 8.27 (d, IH), 8.19 (d, 1H),
7.90 (d, 0.6H), 7.83 (d, 0.4H), 7.65 (m, 2H), 7.34(d, 2H), 7.00 (dd, IH), 6.92 (d, 2H), 5.10
(s, 2H), 4.80 (s, 1.2H), 4.60 (s, 0.8H), 4.25 (s, 0.8H), 4.00 (s, 1.2H), 3.77 (s, 3H), 3.56 (t,
1.2H), 3.39 (m,2H), 3.21 (t, 0.8H).
(003631 EXAMPLE 39 - N-2-(Benzothiazole-2-sulfonylamino)-ethyI]-N-{[4-N-(3,4-
dimethoxybenzyloxycarbony l)-cytosin-1 -yl]-acetyl} -glycine
(00364) The title compound (607 mg, 92 %) was synthesized from N-[2-(benzothiazole-
2-sulfonylamino)-ethyl]-N-{[4-N-(3,4-dimethoxybenzyloxycarbonyl)-cytosin-l-yl]-acetyl}-
glycine ethyl ester (689 mg, 1.0 mmol) as per the procedure of Example 36. 1H NMR (500
MHz; DMSO-d„) δ 10.85 (brs, IH), 8.88 (t, 0.6H), 8.75 (t, 0.4H), 8.28 (d, IH), 8.19 (d, IH),
7.90 (d, 0.6H), 7.83 (d, 0.4H), 7.66 (m, 2H), 7.03 (s, iH), 7.01 (dd, IH), 6.93 (s, 2H), 5.09
(s, 2H), 4.79 (s, 1.2H), 4.60 (s, 0.8H), 4.25 (s, 0.8H), 3.99 (s, 1.2H), 3.75 (s, 3H), 3.74 (s,
3H), 3.56 (t, 1.2H), 3.40 (m, 2H), 3.20 (dd, 0.8H).
(003651 EXAMPLE 40 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[4-N-
(piperonyloxycarbonyl)-cytosin-1-yl]-acetyl)-glycine
(366) The title compound (632 mg, 92 %) was synthesized from N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-N-{[4-N-(piperonyloxycarbonyl)-cytosin-l-yl]-acetyl}-glycine ethyl ester (673 mg, 1.0 mmol) as per the procedure of Example 36. 1H NMR (500 MHz; DMSO-d6) δ 10.72 (brs, IH), 8.25 (d, IH), 8.18 (d, IH), 7.89 (d, 0.4H), 7.82 (d, 0.6H), 7.63 (m, 2H), 6.98 (s, IH), 6.97 (dd, iH), 6.90 (s, 2H), 6.00 (s, 2H), 5.06 (s, 2H), 4.77 (s, 0.8H), 4.54 (s, 1.2H), 3.90 (s, 2H), 3.58 (t, 1.2H), 3.40 (m, 1.6H), 3.20 (t, 1.2H).
(367) EXAMPLE 41 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[4-N-(2-methylthioethoxycarbonyl)-cytosin-1 -yl]-acetyl}-glycine
(368) The title compound (537 mg, 92 %) was synthesized from of N-[2-(ben2othiazole-2-sulfonylamino)-ethyl]-N-{[4-N-(2-methylthJoethoxycarbonyl)-cytosin-l-yl]-acetyl}-glycine ethyl ester (613 mg, 1.0 mmol) as per the procedure of Example 36. 1H
NMR (500 MHz; DMSO-d6) δ 8.87 (t, 0.6H), 8.74 (t, 0.4H), 8.28 (dd, IH), 8.19 (m, IH), 7.90 (d, 0.6H), 7.83 (d, 0.4H), 7.66 (m, 2H), 6.98 (m, IH), 4.80 (s, 1.2H), 4.61 (s, 0.8H),
4.26 (t, 3H), 4.25 (s, 0.8H), 4.00 (q, 1.2H), 3.57 (t, 1.2H), 3.40 (m, 2.0H), 3.22 (q, 0.8H),
2.73 (t,2H), 2.12 (s,3H).
[00369] EXAMPLE 42 - /V-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[6-N-
(benzhydiyloxycaibonyl)-adenin-9-yl]-acetyl}-glycine
[00370] The title compound (631 mg, 90 %) was synthesized from of N-[2-
(benzothiazolc-2-sulfonylamino)-cthyl]-N-{[6-N-(beiizhydryloxycarbonyl)-adenin-9-yl]-
acetyl}-glycine ethyl ester (729 mg, 1.0 mmol) as per the procedure of Example 36. 1H-
NMR (500 MHz; DMSO-d6) δ 11.00 (s, 1H). 9.00 (br, 1H), 8.55 (d, 1H), 8.32 (d, 1H), 8.26
(m, lH),8.17(m, 1H), 7.64 (m, 2H), 7.52-7.26 (m, 10H),6.8I (s, IH),5.35(s, 1H), 5.13 (s,
1H), 4.33 (s, 1H), 4.00 (s, 1H), 3.67 (t, 1H), 3.48 (t, IH), 3.40 (t, 1H), 3.22 (t, 1H).
I00371J EXAMPLE 43 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[6-N-(4-
methoxybenzyloxycarbonyl)-adcnin-9-yl]-acetyl}-glycine
[00372] The title compound (596 mg, 91 %) was synthesized from of N-[2-
(benzothiazole-2-sulfonylamino)-cthyI]-N-{[6-A'-(4-methoxybenzyloxycarbonyl)-adenin-9-
yl]-acetyl}-glycine ethyl ester (683 mg, 1.0 mmol) as per the procedure of Example 36. 'H
NMR (500 MHz; DMSO-d6) δ 11.75 (brs, 1H), 8.57 (d, 1H), 8.37 (d, 1H), 8.27 (d, 1H),
3.18 (dd, 1H), 7.65 (m, 2H), 7.39 (d, 2H), 6.94 (d, 2H), 5.36 (s, 1H), 5.15 (s, 3H), 4.37 (s,
1H), 4.01 (s, 1H), 3.75 (s, 3H), 3.68 (t, 1H), 3.48 (q, IH), 3.40 (q, 1H), 3.22 (q, 1H).
100373] EXAMPLE 44 - N-t2-(Benzothiazole-2-sulfonylamino)-ethyl]-A'-{[6-N-(3,4-
dimethoxybenzyloxycarbonyl)-adenin-9-yl]-acetyl}-glycine
|00374] The title compound (597 mg, 87 %) was synthesized from of A42-
(benzothiazole-2-sulfonylamino)-ethyl]-A^[6-A^3,4-dimethoxybenzyloxycarbonyl)-
adenin-9-yl]-acetyl}-glycine ethyl ester (713 rng, 1.0 mmol) as per the procedure of
Example 36. 1H NMR (500 MHz; DMSO-d6) δ 11.60 (brs, 1H), 8.56 (s, 0.5H), 8.53 (s,
0.5H), 8.29 (d, 1H), 8.27 (d, 1H), 8.18 (dd, 1H), 7.64 (m, 2H), 7.08 (s, IH), 6.98 (d, 1H),
6.94 (d, IH), 5.34 (s, IH), 5.13 (s, IH), 5.12 (s, 2H), 4.36 (s, IH), 4.00 (s, IH), 3.76 (s, 3H),
3.74 (s, 3H), 3.67 (t, IH), 3.48 (q, IH), 3.40 (q, IH), 3.22 (q, IH).
[00375] EXAMPLE 45 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[6-N-
(piperonyloxycarbonyl)-adenin-9-yl]-acetyl}-glycine
(00376] The title compound (629 mg, 94 %) was synthesized from of N-[2-
(benzothiazole-2-sulfonylamino)-ethyl]-N-{[6-N-(piperonyloxycarbonyl)-adenin-9-yl]-
acetyl}-glycine ethyl ester (697 mg, 1.0 mmol) as per the procedure of Example 36. 1H
NMR (500 MHz; DMSO-d6) δ 11.65 (brs, IH), 8.55 (s, 0.5H), 8.53 (s, 0.5H), 8.30 (s, 0.5H),
8.27 (s, 0.5H), 8.25 (d, IH), 8.17 (dd, IH), 7.64 (m, 2H), 7.04 (s, IH), 6.94 (d, IH), 6.90 (d,
1H), 6.01 (s, 2H), 5.34 (s, 1H), 5.09 (s, 3H), 4.20 (s, 1H), 3.98 (s, 1H), 3.67 (t, 1H), 3.49 (1,
1H), 3.41 (t, 1H), 3-23 (t, 1H).
[00377] EXAMPLE 46 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[6-N-(2-
methylthioethoxycarbonyl)-adenin-9-yl]-acetyl}-glycine
[00378] The title compound (560 mg, 92 %) was synthesized from of N-[2-
(benzothiazole-2-sulfonylamino)-ethyl]-N-{[6-N-(2-methylthioethoxycarbonyl)-adenin-9-
yl]-acetyl} -glycine ethyl ester (637 mg, 1.0 mmol) as per the procedure of Example 36.
(379) EXAMPLE 47 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[2-N-(benzhydryloxycarbonyl)-guanin-9-yl]-acetyl}-glycine
(380) The title compound (645 mg, 90 %) was synthesized from of N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-N-{[2-N-(benzhydryloxycarbonyl)-guanin-9-yl]-acetyl}-glycine ethyl ester (745 mg, 1 mmol) as per the procedure of Example 36.1H NMR
(500 MHz; DMSO-d6) δ 11.68 (d, 1H), 11.26 (brs, 2H), 8.94 (t, 0.6H), 8.76 (t, 0.4H), 8.27 (d, 1H), 8.17 (m, 1H), 7.90 (s, 0.6H), 7.87 (s,0.4H), 7.65 (m, 2H), 7.50-7.25 (m, 10H), 6.86 (s, IH), 5.12 (s, I.2H), 4.94 (s, 0.8H), 4.35 (s, 0.8H), 4.00 (s, 1.2H), 3.62 (m, 1.2H), 3.40 (m, 2H), 3.22 (m, 0.8H).
100381 j EXAMPLE 48 - A'-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[2-N-(4-
methoxybenzyloxycarbonyl)-guanin-9-y l]-acetyl}-glycine
(00382) The title compound (643 mg, 92 %) was synthesized from of N-[2-
(benzothiazole-2-sulfonylamino)-ethyl]-N-{[2-N-(4-methoxybenzyIoxycarbonyl)-guanin-9-
yl)-acetyl}-glycine ethyl ester (699 mg, 1 mmol) as per the procedure of Example 36. lH
NMR (500 MHz; DMSO-d6) δ 8.92 (t, 0.6H), 8.76 (t, 0.4H), 8.26 (dd, IH), 8.16 (dd, IH),
7.80 (s, 0.6H), 7.75 (s, 0.4H), 7.67-7.61 (m, 2H), 7.36 (d, 2H), 6.94 (d, 2H), 5.16 (s, 2H),
5.08 (s, 1.2H), 4.89 (s, 0.8H), 4.33 (s, 0.8H), 4.00 (s, 1.2H), 3.74 (s, 3H), 3.60 (t, 1.2H),
3.43 (t, 0.8H), 3.38 (m, 1.2H), 3.22 (m, 0.8H).
100383) EXAMPLE 49 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[2-N-(3,4-
dimethoxybenzyloxycarbonyl)-guanin-9-yl]-acetyl}-glycine
(00384) The title compound (603 mg, 86 %) was synthesized from of N-[2-
(benzothiazole-2-sulfonylamino)-ethyl]-N-{[2-N-(3,4-dimethoxybenzyloxycarbonyl)-
guanin-9-yl]-acetyl}-glycine ethyl ester (729 mg, 1 mmol) as per the procedure of Example
36. 1H NMR (500 MHz; DMSO-d6) δ 11.36 (s, 0.5H), 11.34 (s, 0.5H), 8.26 (d, IH), 8.16
(dd, 1H), 7.80 (s, 0.5H), 7.75 (s, 0.5H), 7.67-7.61 (m, 2H), 7.03 (s, IH), 6.97-6.94 (m, 2H),
5.15 (s, 2H), 5.08 (s, IH), 4.88 (s, IH), 4.26 (s, IH), 3.98 (s, IH), 3.75 (s, 3H), 3.74 (s, 3H),
3.60 (t, IH), 3.43 (t, IH), 3.38 (t, IH), 3.21 (t, IH).
|00385] EXAMPLE 50 - N-[2-(Benzothiazole-2-sulfonylaimno)-ethyl]-N-{[2-N-
(piperonyloxycarbonyI)-guanin-9-yl]-acetyl}-glycine
|00386] The title compound (630 mg. 92 %) was synthesized from of N-[2-
(bcnzothiazole-2-sulfonylamino)-cthyl]-N-{[2-N-(piperonyloxycarbonyl)-guanin-9-yl]-
acetyl} -glycine ethyl ester (713 mg, 1 mmol) as per the procedure of Example 36. 1H NMR
(500 MHz; DMSO-d6) δ 11.36 (s, 0.5H), 11.35 (s, 0.5H), 8.25 (d, 1H), 8.16 (dd, 1H), 7.81
(s, 0.5H), 7.76 (s, 0.5H), 7.68-7.61 (m, 2H), 7.00 (s, 1H), 6.91 (s, 2H), 6.01 (s, 2H), 5.12 (s,
2H), 5.09 (s, 1H), 4.89 (s, 1H), 4.25 (s, 1H), 3.99 (s, 1H), 3.61 (t, 1H), 3.44 (t, 1H), 3.39 (t,
1H), 3.21 (t, 1H).
|00387] EXAMPLE 51 - N-[2-(Benzothiazole-2-sulfonylamino)-ethyl]-N-{[2-N-(2-
methylthioethoxycarbonyl)-guanin-9-yl]-acetyl}-glycine
[003881 The title compound (581 mg, 93 %) was synthesized from of N-[2-
(benzothiazole-2-sulfonylamino)-ethyl]-N-{[2-N-(2-methylthioethoxycarbonyl)-guanin-9-
yl]-acetyl}-glycine ethyl ester (653 mg, 1 mmol) as per the procedure of Example 36. 'H
NMR (500 MHz; DMSO-d6) δ 11.35 (s, 0.5H), 11.32 (s, 0.5H), 8.26 (d, 1H), 8.16 (dd, 1H),
7.82 (s, 0.5H), 7.79 (s, 0.5H), 7.67-7.61 (m, 2H), 5.08 (s, 1H), 4.90 (s, 1H), 4.33 (s, 1H),
4.30 (t, 2H), 3.99 (s, 1H), 3.62 (t, 1H), 3.45 (t, 1H), 3.39 (t, 1H), 3.20 (t, 1H), 3.13 (t, 2H),
2.51 (s,3H).
[00389] EXAMPLE 52 - l-(Benzothiazole-2-sulfonyl)-4-[(thymin-l-yl)-acetyl]-
piperazin-2-one
[00390] To the mixture of l-(benzothiazole-2-sultbnyl)-piperazin-2-one trifluoroacetic
acid salt (0.83 g, 2.5 mmol), (thymin-l-yl)-acetic acid (0.46g, 2.5mmol), and PyBOP (1.43
g, 2.75 mmol) in DMF (12 mL) was added diisopropylethylamine (0:61ml, 3.75 mmol) at
ambient temperature. The resulting reaction mixture was stirred for 4 h at the same
temperature and the solvent was removed in vacuo. The residue was dissolved in
dichloromethane (20 mL) and the solution was washed with water, saturated sodium
bicarbonate solution, IN HC1 solution, and saline. The resulting solution was dried over
magnesium sulfate and filtered. The filtrate was evaporated in vacuo. The resulting residue
was recrystallized in dichloromethane-ethyl ether to afford the title compound. 1H NMR
(500 MHz; DMSO-d6) δ 11.30 (d, 1H), 8.34 (d, 1H), 8.26 (m, 1H), 7.71 (m, 2H), 7.34 (s,
0.6H), 7.27 (s, 0.4H), 4.67 (s, 1.2H), 4.57 (s, 0.8H), 4.42 (s, 0.8H), 4.27 (s, I.2H), 4.21 (t,
1.2H), 4.07 (t, 0.8H), 3.95 (t, 1.2H), 3.85 (t, 0.8H), 1.74 (s, 3H).
[00391] EXAMPLE 53 - l-(4-Chloro-5-methoxy-benzothiazole-2-sulfonyl)-4-[(thymin-
1 -yl)-acetyl]-piperazin-2-one
[00392] The title compound was synthesized by the reaction of l-(4-chloro-5-melhoxy-
benzothiazole-2-sulfonyl)-pipcrazin-2-one trifluoroacetic acid salt with [4-N-
(benzyloxycarbonyl)-cytosin-l-yl]-acetic acid as per the procedure of Example 52. 'H NMR
(500 MHz; DMSO-d6) δ 11.30 (s, 0.6H), 11.29 (s, 0.4H), 8.27 (d, 1H), 7.66 (d, 1H), 7.33 (s,
0.6H), 7.27 (s, 0.4H), 4.67 (s, 1.2H), 4.57 (s, 0.8H), 4.42 (s, 0.8H), 4.28 (s, 1.2H), 4.21 (t,
1.2H), 4.07 (t, 0.8H), 3.99 (s, 311), 3.95 (t, 1.2H), 3.85 (t, 0.8H).
[00393] EXAMPLE 54 - l-(Benzothiazole-2-sulfonyl)-4-{[4-N-(benzyloxycarbonyl)-
cytosin-1 -yl]-acetyl} -piperazin-2-one
|00394] The title compound was synthesized by the reaction of l-(benzothiazole-2-
sulfonyl)-piperazin-2-one trifluoroacetic acid salt with [4-N-(benzyloxycarbonyl)-cytosin-l-
yl]-acetic acid as per the procedure of Example 52,1H NMR (500 MHz; DMSO-d6) δ 10.79
(brs, IH), 8.34 (m, 1H), 8.26 (m, 1H), 7.91 (d, 0.6H), 7.85 (d, 0.4H), 7.45-7.30 (m, 5H),
7.10 (t, 1H), 5.18 (s, 2H), 4.82 (s, 1.2H), 4.72 (s, 0.8H), 4.45 (s, 0.8H), 4.28 (s, 1.2H), 4.22
(t, 1.2H), 4.07 (t, 0.8H), 3.99 (t, 1.2H), 3.86 (t, 0.8H).
[00395] EXAMPLE 55 - l-(Benzothiazole-2-sulfonyl)-4-{[4-A/-
(benzhydryloxycarbonyl)-cytosin-1 -yl]-acetyl} -piperazin-2-one
[00396] The title compound was synthesized by the reaction of l-(benzothiazole-2-
sulfonyl)-piperazin-2-one trifluoroacetic acid salt with [4-N-(benzhydryloxycarbonyl)-
cytosin-l-yl]-acetic acid as per the procedure of Example 52. 1H NMR (500 MHz; DMSO-
d6) δ 11.00 (brs, 1H), 8.34 (m, 1H), 8.26 (m, 1H), 7.90 (d, 0.6H), 7.84 (d, 0.4H), 7.72 (m.
2H), 7.44 (d, 4H), 7.37 (t, 4H), 7.29 (t, 2H), 6.94 (t, 1H), 6.79 (s, 1H), 4.82 (s, 1.2H), 4.72
(s, 0.8H), 4.45 (s, 0.8H), 4.28 (s, 1.2H), 4.22 (t, 1.2H), 4.07 (t, 0.8H), 3.99 (t, 1.2H), 3.86 (t,
0.8H).
(00397) EXAMPLE 56 - l-(Benzothiazole-2-suIfonyl)-4-{[4-N-(4-
melhoxybcnzyloxycarbonyl)-cytosin-l-yi]-acetyl}-piperazin-2-one
|00398] The title compound was synthesized by the reaction of 1-(benzothiazoIe-2-
sulfonyl)-piperazin-2-one trifluoroacetic acid salt with [4-N-(4-
methoxybenzyloxycarbonyl)-cytosin-l-yi]-acetic acid as per the procedure of Example 52.
1H NMR (500 MHz; DMSO-d6) δ 10.70 (bs, 1H), 8.34 (m, 1H), 8.26 (m, IH), 7.90 (d,
0.6H), 7.84 (d, 0.4H), 7.72 (m, 2H), 7.34 (d, 2H), 7.01 (t, IH), 6.93 (d, 2H), 5.10 (s, 2H),
4.81 (s, 1.2H), 4.71 (s, 0.8H), 4.45 (s, 0.8H), 4.27 (s, 1.2H), 4.22 (t, 1.2H), 4.07 (t, 0.8H),
3.99 (t, 1.2H), 3.85 (t, 0.8H), 3.74 (s, 3H).
|00399| EXAMPLE 57 l-(Benzothiazole-2-sulfonyl)-4-{[4-A'-(3,4-
dimethoxybenzyloxycarbonyl)-cytosin-l-yl]-acetyl}-piperazin-2-one
[00400] The title compound was synthesized by the reaction of 1 -(benzothiazole-2-
sulfonyi)-piperazin-2-one trifluoroacetic acid salt with [4-JV-(3,4-
dimethoxybenzyloxycarbonyl)-cytosin-l-yl]-acctic acid as per the procedure of Example
52. 1H NMR (500 MHz; DMSO-d6) δ 10.73 (brs, 1H), 8.34 (m, 1H), 8.26 (m, 1H), 7.90 (d,
0.6H), 7.84 (d, 0.4H), 7.71 (m, 2H), 7.03 (s, IH), 7.02 (t, 1H), 6.94 (s, 2H), 5.09 (s, 2FI),
4.82 (s, I.2H), 4.72 (s, 0.8H), 4.45 (s, 0.8H), 4.27 (s, 1.2H), 4.21 (t, 1.2H), 4.06 (t, 0.8H),
3.99 (t, 1.2H), 3.85 (t, 0.8H), 3.75(s, 3H), 3.74 (s, 3H).
|00401] EXAMPLE 58 - 1-(Benzothiazole-2-sulfonyl)-4-N-(piperonyloxycarbonyl)-
cytosin-1 -yl]-acetyl} -piperazin-2-one
(00402| The title compound was synthesized by the reaction of l-(benzothiazole-2-
sulfonyl)-piperazin-2-one trifluoroacetic acid salt with [4-N-(piperonyloxycarbonyl)-
cytosin-l-yl]-acetic acid as per the procedure of Example 52. 1H NMR (500 MHz; DMSO-
d6) δ 10.76 (brs, IH), 8.36 (m, IH), 8.28 (m, IH), 7.92 (d, 0.6H), 7.86 (d, 0.4H), 7.73 (m,
2H), 7.03 (t, IH), 7.00 (s, IH), 6.92 (s, 2H), 6.03 (s, 2H), 5.08 (s, 2H), 4.84 (s, 1.2H), 4.74
(s, 0.8H), 4.47 (s, 0.8H), 4.30 (s, 1.2H), 4.24 (t, 1.2H), 4.08 (t, 0.8H), 4.01 (t, 1.2H), 3.89 (t,
0.8H).
[00403] EXAMPLE 59 - l-(Benzothiazole-2-sulfonyl)-4-{[4-A'-(2-
methyIthioethoxycarbonyl)-cytosin-l-yl]-acetyl}-piperazin-2-one
|00404] The title compound was synthesized by the reaction of I-(benzothiazole-2-
sulfonyl)-piperazin-2-one trifluoroacetic acid salt with [4-N-(2-methylthioethoxycarbonyl)-
cytosin-l-yl]-acctic acid as per the procedure of Example 52. 1H NMR (500 MHz; DMSO-
d6) δ 10.72 (brs, 1H), 8.34 (m, IH), 8.26 (m, 1H), 7.90 (d, 0.6H), 7.84 (d, 0.4H), 7.72 (m,
2H), 7.01 (t, IH), 4.82 (s, 1.2H), 4.71 (s, 0.8H), 4.45 (s, 0.8H), 4.27 (s, 1.2H), 4.26 (t, 2H),
4.22 (t, 1.2H), 4.07 (t, 0.8H), 3.99 (t, 1.2H), 3.86 (t, 0.8H), 2.73 (t, 2H), 2.11 (s, 3H).
[00405] EXAMPLE 60 - l-(5-Chloro-benzothiazole-2-sulfonyl)-4-{[4-JV-
(benzhydryloxycarbony l)-cytosin-1-yl]-acety 1}-piperazin-2-one
[00406] The title compound was synthesized by the reaction of l-(5-chloro-
benzothiazole-2-sulfonyl)-piperazin-2-one trifluoroacetic acid salt with [4-N-
(benzhydryloxycarbonyl)-cytosin-l-yi]-acetic acid as per the procedure of Example 52. 'H
NMR (500 MHz; DMSO-d6) δ 10.98 (brs, IH), 8.40 (m, 2H), 7.96 (s, IH), 7.79 (m, IH),
7.45 (d, 4H), 7.38 (t, 4H), 7.30 (t, 2H), 6.96 (t, IH), 6.80 (s, IH), 4.83 (s, 1.2H), 4.72 (s,
0.8H), 4.46 (s, 0.8H), 4.28 (s, 1.2H), 4.22 (t, 1.2H), 4.06 (t, 0.8H), 3.99 (t, 1.2H), 3.87 (t,
0.8H).
[00407] EXAMPLE 61 - l-(Bcnzothiazole-2-sulfonyl)-4-{[6-A'-(benzyloxycarbonyl)-
adcnine-9-yl]-acetyl}-piperazin-2-one
[004081 The title compound was synthesized by the reaction of l-(benzothiazole-2-
suifonyl)-piperazin-2-one trifluoroacetic acid salt with [6-N-(benzyloxycarbonyl)-adenine-
9-yl]-acetic acid as per the procedure of Example 52. 1H NMR (500MHZ; DMSO-d6) δ
10.81 (brs, 1H), 8.60 (d, 1H), 8.36 (m, IH), 8.28 (m, 2H), 7.73 (m, 2H), 7.46 (d, 2H), 7.40
(t, 2H), 7.34 (t, IH), 5.41 (s, 1.2H), 5.29 (s, 0.8H), 5.23 (s, 2H), 4.57 (s, 0.8H), 4.28 (s,
2.4H), 4.09 (m, 2.0H), 3.88 (t, 0.8H).
100409] EXAMPLE 62 - l-(Benzothiazole-2-sulfonyl)-4-{[6-N-
(benzhydryloxycarbonyl)-adeninc-9-yl]-acetyl}-piperazin-2-one
|00410] The title compound was synthesized by the reaction of l-(benzothiazole-2-
sulfonyl)-piperazin-2-one trifluoroacetic acid salt with [6-N-(benzhydryloxycarbonyl)-
adenine-9-yl]-acetic acid as per the procedure of Example 52. 1H NMR (500 MHz; DMSO-
d6) δ 11.15 (brs, IH), 8.60 (d, IH), 8.45-8.32 (m, 2H), 8.26 (m, IH), 7.72 (m, 2H), 7.52 (d,
4H), 7.38 (t, 4H), 7.29 (t, 2H), 6.83 (s, IH), 5.41 (s, 1.2H), 5.30 (s, 0.8H), 4.57 (s, 0.8H),
4.28 (s, 2.4H), 4.09 (brs, 2.0H), 3.88 (t, 0.8H).
|00411] EXAMPLE 63 - l-(Benzothiazole-2-sulfonyl)-4-{[6-N-(4-
methoxybenzyloxycarbonyl)-adenin-9-yl]-acetyl}-piperazin-2-one
[00412] The title compound was synthesized by the reaction of l-(benzothiazole-2-
sulfonyl)-piperazin-2-one trifluoroacetic acid salt with [6-N-(4-
methoxybenzyloxycarbonyl)-adenine-9-yl]-acetic acid as per the procedure of Example 52.
1H NMR (500 MHz; DMSO-d6) δ 10.60 (bs, IH), 8.59 (d, IH), 8.34 (m, 2H), 8.27 (m, IH),
7.72 (m, 2H), 7.38 (d, 2H), 6.94 (d, 2H), 5.40 (s, 1.2H), 5.28 (s, 0.8H), 5.14 (s, 2H), 4.56 (s,
0.8H), 4.28 (m, 2.4H), 4.09 (t, 2H), 3.87 (t, 0.8H), 3.75 (s, 3H).
[00413] EXAMPLE 64 - l-(Benzothiazole-2-sulfonyl)-4-{[6-N-(3)4-
dimethoxybenzyloxycarbonyl)-adenin-9-yl]-acetyl}-piperazin-2-one
|00414] The title compound was synthesized by the reaction of l-(benzothiazolc-2-
sulfbnyl)-piperazin-2-one trifluoroacetic acid salt with [6-N-(3,4-
dimethoxybenzyloxycarbonyl)-adenine-9-yl]-acetic acid as per the procedure of Example
52. 1H NMR (500 MHz; DMSO-d6) δ 10.58 (s, IH), 8.58 (s, 0.6H), 8.56 (s, 0.4H), 8.35 (m,
IH), 8.30 (s, 0.4H), 8.27 (s, 0.6H), 8.26 (m, IH), 7.73 (m, 2H), 7.07 (s, IH), 6.98 (d, IH),
6.94 (d, IH), 5.38 (s, 1.2H), 5.27 (s, 0.8H), 5.12 (s, 2H), 4.56 (s, 0.8H), 4.28 (m, 2.4H), 4.09
(t, 2H), 3.87 (t, 0.8H), 3.76 (s, 3H), 3.74 (s, 3H).
[00415] EXAMPLE 65 - l-(Benzothiazole-2-sulfonyl)-4-{[6-N-(pipcronyloxycarbonyl)-
adcnin-9-yl]-acetyl}-piperazin-2-one
[00416] The title compound was synthesized by the reaction of l-(benzothiazole-2-
sulfonyl)-piperazin-2-onc tnfluoroacetic acid salt with [6-N-(piperonyloxycarbonyl)-
adenine-9-yl]-acetic acid as per the procedure of Example 52. 1H NMR (500 MHz; DMSO-
d6) δ 10.64 (s, 1H), 8.58 (s, 0.6H), 8.57 is, 0.4H), 8.34 (m, 1H), 8.31 (s, 0.4H), 8.28 (s,
0.6H), 8.27 (m, 1H), 7.72 (m, 2H), 7.04 (s. 1H), 6.94 (d, 1H), 6.90 (d, IH), 6.01 (s, 2H),
5.39 (s, 1.2H), 5.28 (s, 0.8H), 5.09 (s, 2H). 4.57 (s, 0.8H), 4.29 (m, 2.4H), 4.09 (t, 2H), 3.88
(t, 0.8H).
[00417] EXAMPLE 66 -I-(Benzothiazole-2-sulfonyl)-4-{[6-N-(2-
methylthioethoxycarbonyl)-adenine-9-yl)acetyl}-piperazin-2-one
[00418] The title compound was synthesized by the reaction of 1 -(benzothiazole-2-
sulfonyl)-piperazin-2-one tnfluoroacetic acid salt with [6-N-(2-methylthioethoxycarbonyl)-
adenine-9-yl]-acetic acid as per the procedure of Example 52. 1H NMR (500 MHz; DMSO-
d6) δ 10.80 (bis, IH), 8.61 (d, IH), 8.42 (s, 0.6H), 8.39 (s, 0.4H), 8.35 (m, IH), 8.27 (m,
IH), 7.73 (m, 2H), 5.42 (s, 1.2H), 5.30 (s. 0.8H), 4.57 (s, 0.8H), 4.34-4.25 (m, 4.4H), 4.09
(m, 2.0H), 3.88 (t, 0.8H), 2.79 (t, 2H), 2.13 (s, 3H)i
(00419) EXAMPLE 67 - l-(Benzothjazole-2-sulfonyi)-4-{[2-JV-(benzyloxycarbony!)-
guanin-9-yl]-acctyl}-piperazin-2-one
|00420] The title compound was synthesized by the reaction of l-(benzothiazole-2-
sulfonyl)-piperazin-2-one tnfluoroacetic acid salt with [2-N-(benzyIoxycarbonyl)-guanin-9-
yl]-acetic acid as per the procedure of Example 52. 1H NMR (500 MHz; DMSO-d6) δ 11.35
(bs, 2H), 8.34 (m, IH), 8.25 (m, IH), 7.81 (s, 0.6H), 7.77 (s, 0.4H), 7.71 (m, 2H), 7.45-7.30
(m, 5H), 5.23 (s, 2H), 5.13 (s, 1.2H), 5.02 (s, 0.8H), 4.51 (s, 0.8H), 4.27 (s, 1.2H), 4.24 (t,
1.2H), 4.08 (t, 0.8H), 4.03 (t, 1.2H), 3.85 (t, 0.8H).
100421] EXAMPLE 68 - l-(Benzothiazole-2-sulfonyl)-4-{[2-N-
(benzhydryloxycarbonyI)-guanin-9-yl]-acetyl}-piperazin-2-one
[00422] The title compound was synthesized by the reaction of l-(benzothiazolc-2-
suIfonyl)-piperazin-2-one tnfluoroacetic acid salt with [2-N-(benzhydryloxycarbonyl)-
guanin-9-yl]-acetic acid as per the procedure of Example 52. 1H NMR (500 MHz; DMSO-
d6) δ 11.62 (bs, H), 11.24 (bs, IH), 8.36 (m, IH), 8.26 (m, IH), 7.81 (s, 0.6H), 7.77 (s,
0.4H), 7.72 (m, 2H), 7.45 (d, 4H), 7.38 (t, 4H), 7.30 (t, 2H), 6.86 (s, IH), 5.16 (s, 1.2H),
5.05 (s, 0.8H), 4.53 (s, 0.8H), 4.28 (s, 1.2H), 4.26 (t, 1.2H), 4.09 (t, 0.8H), 4.05 (t, 1.2H),
3.86 (t, 0.8H).
[004231 EXAMPLE 69 l-(Benzothiazole-2-sulfonyl)-4-{[2-N-(4-
methoxybenzyloxycarbonyl)-guanin-9-yl]-acetyl}-piperazin-2-one
[00424) The title compound was synthesized by the reaction of l-(bcnzothiazole-2-
sulfonyl)-piperazin-2-one trifluoroacetic acid salt with [2-N-(4-
methoxybenzyloxycarbonyl)-guanin-9-yI]-ncetic acid as per the procedure of Example 52.
1H NMR (500 MHz; DMSO-de) δ 11.38 (bs, 2H), 8.33 (m, 1H), 8.24 (m, 1H), 7.81 (d,
0.6H), 7.77 (d, 0.4H), 7.71 (m, 2H), 7.36 (d. 2H), 6.94 (d, 2H), 5.16 (s, 2H), 5.12 (s, 1.2H),
5.02 (s, 0.8H), 4.51 (s, 0.8H), 4.26 (s, 1.2H), 4.24 (t, 1.2H), 4.08 (t, 0.8H), 4.03 (t, 1.2H),
3.85 (t,0.8H), 3.75 (s,3H).
[00425J EXAMPLE 70 - l-(Benzothiazole-2-sulfonyl)-4-{[2-N-(3,4-
dimethoxybenzyloxycarbonyl)-guanin-9-yl]-aceryl}-piperazin-2-one
[00426] The title compound was synthesized by the reaction of l-(benzothiazole-2-
sulfonyl)-piperazin-2-one trifluoroacetic acid salt with [2-N-(3,4-
dimethoxybenzyloxycarbonyl)-guanin-9-yl]-acetic acid as per the procedure of Example 52.
1H NMR (500 MHz; DMSO-d0) δ 11.41 (s, IH), 11.37 (s, 1H), 8.34 (m, 1H), 8.24 (m, 1H),
7.81 (S.0.6H), 7.77 (S.0.4H), 7.71 (m, 2H). 7.04 (s, lH),6.95(d, JH),6.94(d, IH), 5.15 (s,
2H), 5.13 (s, I.2H), 5.02 (s, 0.SH), 4.51 (s, 0.8H), 4.27 (s, 1.2H), 4.24 (t, 1.2H), 4.07 (t,
0.8H), 4.03 (t, 1.2H), 3.84 (t, 0.8H), 3.75 (s. 3H), 3.74 (s, 3H).
[00427} EXAMPLE 71 - l-(Benzothiazole-2-sulfonyl)-4-{[2-N-(piperonyloxycarbonyl)-
guanin-9-yl]-acetyl}-piperazin-2-one
[00428] The title compound was synthesized by the reaction of l-(benzothiazole-2-
sulfonyl)-piperazin-2-one trifluoroacetic acid salt with [2-N-(piperonyloxycarbonyl)-
guanin-9-yl]-acetic acid as per the procedure of Example 52. 1H NMR (500 MHz; DMSO-
d6) δ 11.40 (brs, 2H), 8.36 (m, IH), 8.27 (m, IH), 7.84 (s, 0.6H), 7.78 (s, 0.4H), 7.73 (m,
2H), 7.02 (s, IH), 6.93 (s, 2H), 6.04 (s, 2H), 5.15 (m, 3.2H), 5.05 (s, 0.8H), 4.55 (s, 0.8H),
4.30 (s, 1.2H), 4.27 (t, 1.2H), 4.11 (t, 0.8H), 4.07 (t, 1.2H), 3.88 (t, 0.8H).
[00429] EXAMPLE 72 - l-(Benzothiazole-2-sulfonyI)-4-{[2-N-(2-
methylthioethoxycarbonyl)-guanin-9-yl]-acetyl}-piperazin-2-one
1004301 The title compound was synthesized by the reaction of l-(benzothiazole-2-
sulfonyl)-piperazin-2-one trifluoroacetic acid salt with [2-N-(2-methylth.ioethoxycarbonyI)-
guantn-9-yl]-acetic acid as per the procedure of Example 52. 1H NMR (500 MHz; DMSO-
de) δ 11.41 (brs, IH), 11.35 (brs, IH), 8.35 (m, IH), 8.25 (m, IH), 7.82 (d, 0.6H), 7.78 (d,
0.4H), 7.72 (m, 2H), 5.14 (s, 1.2H), 5.03 (s, 0.8H), 4.51 (s, 0.8H), 4.32 (t, 2H), 4.27 (s,
1 2H), 4.24 (t, 1.2H), 4.08 (t, 0.8H), 4.04 (t, 1.2H), 3.85 (t, 0.8H), 2.75 (t, 2H), 2.12 (s, 3H).
I00431] EXAMPLE 73 - l-(5-Chloro-benzothiazole-2-sulfonyl)-4-{[2-N-
(benzhydryloxycarbonyl)-guanin-9-yl]-acetyl}-piperazin-2-one
[00432] The title compound was synthesized by the reaction of l-(5-chloro-
benzothiazole-2-sulfonyl)-piperazin-2-one tnfluoroacetic acid salt with [2-N-
(bcnzhydryloxycarbonyl)-guanin-9-yl]-acetic acid as per the procedure of Example 52. 'tl
NMR (500 MHz; DMSO-dfi) δ 11.62 (brs, H), 11.25 (brs, 1H), 8.42-8.39 (m, 1H), 7.96 (s,
0.6H), 7.82 (s, 0.4H), 7.78 (m, 1H), 7.46 (d, 4H), 7.39 (t, 4H), 7.31 (t, 2H), 6.87 (s, 1H),
5.17 (s, 1.2H), 5.06 (s, 0.8H), 4.53 (s, 0.8H), 4.29 (s, 1.2H), 4.25 (t, 1.2H), 4.08-4.06 (m,
2H), 3.87 (t, 0.8H).
[00433] EXAMPLE 74 - l-(Benzothiazole-2-sulfonyl)-4-[thymin-l-yl]-acetyl-3-methyl-
piperazin-2-one
|00434] The title compound was synthesized by the reaction of l-(benzothiazole-2-
sulfonyl)-3-methyl-piperazin-2-one trifluoroacetic acid salt with (thymin-1-yl)-acetic acid
as per the procedure of Example 52. 1 H NMR (500 MHz; DMSO-d6) δ 11.31 (brs, 1H), 8.34
(m, 1H), 8.25 (m, 1H), 7.72 (m, 2H), 7.36 (s, 1H), 4.85-4.60 (m, 2.5H), 4.55-4.40 (m,
0.5H), 4.25-4.10 (m, 2.5H), 3.85-3.74 (m, 0.5H), 3.50-3.30 (m, 1H), 1.75 (s, 3H), 1.44 (d,
lH),1.29(d.2H).
[00435| EXAMPLE 75 -l-(Benzothiazole-2-sulfonyl)-4-[(thymin-l-yl)-acetyl]-
piperazin-2-one
[00436] Method A
[00437] To a solution of N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-N-[(thymin-l-yl)-
acelyl]-glycine (963 mg, 2 imnole) in tetrahydrofuran (50 mL) was added N-methyl
morpholine (3.3 mL, 3 mmole) and then the mixture was cooled to -20 °C. After stirring
for 5 min at the same temperature, chloroisobutylformate (3.4 mL, 26 mmole) was added to
the reaction mixture. The resulting mixture was slowly warmed to 0 °C for 1 h. Then the
reaction mixture was evaporated in vacuo and dissolved in a mixture of ethyl acetate and
acetonitrile. The solution was washed with brine and dried over sodium sulfate and filtered.
The filtrate was evaporated in vacuo and triturated with TETRAHYDROFURAN-ethyl
ether (1/1, v/v) to precipitate solid. The solid was filtered off, washed with ethyl ether, and
dried in vacuo to give the titled compound (834 mg, 90 %).
[00438] Method B
[00439] The mixture of N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-N-[(thymin-l-yl)-
acetyl]-glycine (963 mg, 2 mmol) and EDC (460 mg, 2.4 mmol) in DMF (10 mL) was
stirred for 6 h at room temperature. The solvent was removed by evaporation in vacuo and
the residue was dissolved in diehloroinethane (30 mL). The solution was washed with IN
HCl solution (20 mL) and water (30 ml.). The organic layer was dried over MgSO4, filtered,
and concentrated to give a yellow residue. The residue was dissolved in acetone and passed
on a short silica gel. The filtrate was evaporated and the residue was dissolved in
tetrahydrofuran. The organic solution was slowly added to ethyl ether to precipitate a whrte
solid, which was collected by filtration, washed with tetrahydrofuran/ethyl ether (1/2, v/v)
and then dried to give the titled compound (862 mg, 93 %). 1H NMR (500 MHz; DMSO-d6)
data are the same as Example 52.
[00440] EXAMPLE 76 - l-(Benzothiazole-2-sulfonyl)-4-{[4-N-
(benzhydryloxycarbonyI)-cytosin-l-yl]acetyl}-piperazin-2-one
[00441] The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-yV-{[4-N-(bcnzhydryloxycarbonyl)]-cytosin-l-yl}-acetyl}-glycine as
per the procedures of method A or B of Example 75. Yield: method A (87 %), method B
(92 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 55.
[00442] EXAMPLE 77 - I-(Benzothiazole-2-sulfonyl)-4-{[4-N-(4-
methoxybenzyloxycarbonyl)-cytosin-1 -yl]acetyl}-piperazin-2-one
[00443] The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-N-{[4-N-(4-methoxybenzyloxycarbonyl)]-cytosin-l-yl}-acetyl}-
glycine as per the procedures of method A or B of Example 75. Yield: method A (85 %),
method B (90 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 56.
[00444] EXAMPLE 78 - l-(Benzothiazole-2-sulfonyl)-4-{[4-N-(3,4-
dimethoxybenzyloxycarbonyl)-cytosin-1 -yljacetyl} -piperazin-2-one
|00445] The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-N-{[4-N-(3,4-dimethoxybenzyloxycarbonyl)]-cytosin-1 -yl} -acetyl} -
glycine as per the procedures of method A or B of Example 75. Yield: method A (85 %),
method B (90 %). 1H NMR (500 MHz: DMSO-d6) data are the same as Example 57.
[00446] EXAMPLE 79 - l-(Benzothiazole-2-sulfonyl)-4-{[4-N-(piperonyloxycarbonyl)-
cytosin-1 -yl]acetyl} -piperazin-2-one
[00447] The title compound was synthesized from N-[2-(benzothiazolt.-2-
sulfonylamino)-ethyI]-N-{[4-N-(piperonyloxycarbonyI)]-cytosin-l-yl}-acetyl}-glycine as
per the procedures of method A or B of Example 75. Yield: method A (91 %), method B
(95 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 58.
[00448] EXAMPLE 80 l-(Benzothiazole-2-sulfonyl)-4-{[4-N-(2-
methylthioethoxycarbonyl)-cytosin-l-yl]acetyl}-piperazin-2-one
[00449] The title compound was synthesized from A'-[2-(henzothiazole-2-
sulfonylamino)-ethyl]-N-{[4-N-(2-metliylthioethoxycarbonyl)]-cytosin-l-yI}-acetyl}-
glycine as per the procedures of method A or B of Example 75. Yield: method A (90 %),
method B (93 %). 1H NMR (500 MHr. DMSO-d6) data are the same as Example 59.
|00450] EXAMPLE SI -l-(Benzothiazole-2-sulfonyl)-4-{[6-N-
(benzhydryloxycarbonyl)-adenin-9-yl]-acetyl}-piperazin-2-one
|00451] The title compound was synthesized from N-[2-(benzothiazole-2-
svilfonylamino)-ethyl]-N-{[6-N-(benzhydryloxycarbonyl)]-adenin-9-yl}-acetyl)-glycine as
per the procedures of method A or B of Example 75. Yield: method A (89 %), method B
(94 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 62.
[00452] EXAMPLE 82 - l-(Benzothiazole-2-sulfonyl)-4-{[6-N-(4-
methoxybenzyIoxycarbonyl)-adenin-9-yl]-acctyl}-piperazin-2-one
[00453] The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-N-{[6-N-(4-methoxybenzyloxycarbonyl)}-adenin-9-yl}-acetyl}-
glycine as per the procedures of method A or B of Example 75. Yield: method A (89 %),
method B (94 %). 1H NMR (500 MHz: DMSO-d6) data are the same as Example 63.
[00454] EXAMPLE 83 - l-(Benzothiazoie-2-suifonyi)-4-{[6-N-(3,4-
dimethoxybenzyIoxycarbonyl)-adenin-9-yl]-acetyl}-piperazin-2-one
|00455] The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-N-{[6-A'-(3,4-dimethoxybenzyloxycarbonyl)]-adenin-9-yl}-acetyl}-
glycine as per the procedures of method A or B of Example 75. Yield: method A (84 %),
method B (89 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 64.
[00456] EXAMPLE 84 - l-(Benzothiazole-2-sulfonyl)-4-{[6-N-(piperonyloxycarbonyl)-
adenin-9-yl]-acetyl}-piperazin-2-one
|00457] The title compound was synthesized from N-[2-(benzothiazole-2-
sul fonylamino)-ethyl]-N-{[6-N-(piperonyloxycarbonyl)]-adenin-9-yl} -acetyl} -glycine as
per the procedures of method A or B of Example 75. Yield: method A (80 %), method B
(88 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 65.
[00458] EXAMPLE 85 l-(Benzothiazole-2-sulfonyl)-4-{[6-A'-(2-
methylthioethoxycarbonyl)-adenin-9-yl]-acetyl}-piperazin-2-one
[00459] The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-N- {[6-N-(2-methy lthioethoxycarbony l)]-adenin-9-yl} -acetyl} -
glycine as per the procedures of method A or B of Example 75. Yield: method A (88 %),
method B (93 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 66.
|00460| EXAMPLE 86 - l-(Bcnzothiazolc-2-sulfonyl)-4-{[2-N-
(benzhydryloxycarbonyl)-gunnin-9-yljacetyl}-piperazin-2-one
[00461] The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-N-{[2-N-(benzhydryloxycarbonyl)]-guanin-9-yI}-acetyl}-glycine as
per the procedures of method A or B of Example 75. Yield: method A (90 %), method B
(92 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 68.
(00462| EXAMPLE 87 - l-(BenzothiazoIe-2-sulfonyl)-4-{[2-H-(4-
methoxybenzyloxycarbonyl)-guanin-9-yl]acetyl}-piperazin-2-one
|00463| The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-N-{[2-N-(4-methoxybenzyloxycarbonyl)]-guanin-9-yl} -acetyl} -
glycine as per the procedures of method A or B of Example 75. Yield: method A (86 %),
method B (88 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 69.
[00464] EXAMPLE 88 - l-(Benzothiazole-2-sulfonyl)-4-{[2-N-(3,4-
dimethoxybenzyloxycarbonyl)-guanin-9-yl]acetyl}-piperazin-2-one
[00465] The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-N-{[2-N-(3,4-dimethoxybenzyloxycarbonyl)]-guanin-9-yl}-acctyI}-
glycine as per the procedures of method A or B of Example 75. Yield: method A (83 %),
method B (86 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 70.
[00466] EXAMPLE 89 - l-(Benzothiazolc-2-su!fonyl)-4-{[2-N-(pipcronyloxycarbonyl)-
guanin-9-yl]acetyl}-piperazin-2-one
[00467] The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-N-{[2-N-(piperonyloxycarbonyl)]-guanin-9-yl}-acetyl}-glycine as
per the procedures of method A or B of Example 75. Yield: method A (92 %), method B
(95 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 71.
(00468] EXAMPLE 90 - I-(Benzothiazole-2-sulfonyl)-4-{[2-N-(2-
methylthioethoxycarbonyl)-guanin-9-yl]acetyl}-piperazin-2-one
[00469] The title compound was synthesized from N-[2-(benzothiazole-2-
sulfonylamino)-ethyl]-N-{[2-N-(2-methylthioethoxycarbonyl)]-guanin-9-yl}-acetyl}-
glycinc as per the procedures of method A or B of Example 75. Yield: method A (86 %),
method B (88 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 72.
[00470] EXAMPLE 91-1 -(Benzothiazole-2-suIfonyl)-4-[thymin-1 -yl]-acetyl-3-methy 1-
piperazin-2-one
[00471] The title compound was synthesized by the reaction of I-(benzothiazole-2-
sulfonyl)-piperazin-2-one trifluoroacetic acid salt with (thymin-l-yl)-acetic acid as per the
procedure of Example 75. Yield: method A (.S3 %), method B (87 %). 1H NMR (500 MHz; DMSO-d6) data are the same as Example 74. [004721 Solid phase Synthesis of PNA Oligomer [00473) General Procedure
[00474] PNA oligomer synthesis was conducted manually on a Nova Syn TG amino, resin (Nova biochem., 0.26 mmol/g loading) which is a PEG-grafted polystyrene resin with amine functionality. The resin was coupled with PAL linker (5-[4-(9-fluorenylmethoxycarbonyl)amino-3,5-dimethoxyphenoxy]pentanoic acid (Advanced ChemTech) by using HBTU as a coupling reagent in DMF. The resulting resin was treated with 20 % piperidine in DMF to activate the amine functional group of PAL linker for PNA oligomer synthesis. The PNA oligomer was synthesized according to the following synthesis cycle. All reactions and washes of the resin were performed in a fritted vial.
[00475J Following is a non-limiting general procedure for solid phase synthesis of PNA
oligomer
|00476] I. Coupling with 10 equiv. of appropriate monomer (20 M in 0.5M acetic acid in
DMF) for 2 h.
[00477] 2. Washing with DMF 3 times.
[00478) 3. Capping with acetic anhydride (5 % acetic anhydride and 6 % lutidine in
DMF) for 5 min.
[00479] 4. Washing with DMF 2 times.
[00480] 5. Cleavage over-reacted acetyl group in sulfonamide with piperidine (1.0 M in
DMF) for 5 min.
[00481] 6. Washing with DMF 3 times.
[00482] 7. Deprotection of benzothiazole-2-sulfonyl group with 4-methoxybenzenethiol
for 15 min.
[00483] 8. Washing with DMF 3 times
(00484] After removal of the final benzothiazole-2-sulfonyl group, the resin is washed
with DMF 3 times and dichloromethane 2 times and dried. The removal the protecting
group of exocyclic amine and cleavage from the resin was performed in one step by
treatment with 25 % m-cresol in TFA for 1.5 h. The resin is filtered off and washed with
TFA. Almost TFA of the combined filtrate is removed by blowing a steady stream of
nitrogen. Then the residue was suspended with ethyl ether and centrifuged. The supernatant
is carefully decanted off. The residue of crude PNA oligomer is washed one more time by
suspension with ethyl ether, centrifuge, and removal of supernatant. The crude PNA
oligomer is analyzed with HPLC and confirmed by Matrix Assisted Laser Desorption-Time
of Flight (MALDI-TOF).
[00485] EXAMPLE 92 - Synthesis of PNA oligomer sequence H2N-CTCGTTTCCA-H
(SEQ ID NO: 1)
[00486] The title sequence was synthesized manually by the above general procedure
using monomer of general formula I, wherein Rl, R2, R3, R4, and R5 are 11 and the
protecting group of exocyclic amine of nucleobases (A, C, and G) is
benzhydryloxycarbonyl. FIGS. 17A-B show (A) HPLC and (B) MALDI-TOF profiles.
|00487| EXAMPLE 93 - Synthesis of PNA oligomer sequence H2N-TCGTGTCGTA-H
(SEQ ID NO:2)
[00488] The title sequence was synthesized manually by the above general procedure
using monomer of general formula I, wherein Rl, R2, R3, R4, and R5 are H and the
protecting group of exocyclic amine of nucleobases (A, C, and G) is
benzhydryloxycarbonyl. FIGS. 18A-B show (A) HPLC and (B) MALDI-TOF profiles.
[00489] EXAMPLE 94 - Synthesis of PNA oligomer sequence H2N-ACCAGCGGCA-H
(SEQ ID NO:3)
|00490] The title sequence was synthesized manually by the above general procedure
using monomer of general formula I, wherein Rl, R2, R3, R4, and R5 are H and the
protecting group of exocyclic amine of nucleobases (A, C, and G) is
benzhydryloxycarbonyl. FIGS. 19A-B show (A) HPLC and (B) MALDI-TOF profiles.
|00491] EXAMPLE 95 - Synthesis of PNA oligomer sequence H2N-TCTTCTAGTG-H
(SEQ ID NO:4)
[00492] The title sequence was synthesized manually by the above general procedure
using monomer of general formula I, wherein Rl, R2, R3, R4, and R5 arc H and the
protecting group of exocyclic amine of nucleobases (A, C, and G) is
benzhydryloxycarbonyl. FIGS. 20A-B show (A) HPLC and (B) MALDI-TOF profiles.
[00493] EXAMPLE 96 - Synthesis of PNA oligomer sequence H2N-GTGCTCCTCC-H
(SEQ ID NO:5)
|00494| The title sequence was synthesized manually by the above general procedure
using monomer of general formula I, wherein Rl, R2, R3, R4, and R5 are H and the
protecting group of exocyclic amine of nucleobases (C and G) is benzhydryloxycarbonyl.
FIGS. 21A-B show (A) HPLC and (B) MALDI-TOF profiles.
[00495] EXAMPLE 97 - Synthesis of PNA oligomer sequence H2N-GTGCATGATG-H
(SEQ ID NO.-6)
[004961 The title sequence was synthesized manually by the above general procedure using monomer of general formula 1, wherein Rl, R2, R3, R4, and R5 are H and the protecting group of exocyclic amine of nucleobases (A. C, and G) is benzhydryloxycarbonyl. FIGS. 22A-B show (A) HPLC and (B) MALDI-TOF profiles. [00497] EXAMPLE 98 - Synthesis of PNA oligomer sequence H2N-CCCTACTGTG-H (SEQ ID NO:7)
[00498] The title sequence was synthesized manually by the above general procedure using monomer of general formula I, wherein Rl, R2, R3, R4, and R5 are H and the protecting group of exocyclic amine of nucleobases (A, C, and G) is benzhydryloxycarbonyl. FIGS. 23A-B show (A) HPLC and (B) MALDI-TOF profiles. [00499] EXAMPLE 99 - Synthesis of PNA oligomer sequence H2N-CTCATTTCCA-H (SEQ ID NO:8)
|00500] The title sequence was synthesized manually by the above general procedure using monomer of general formula 1, wherein Rl, R2, R3, R4, and R5 are H and the protecting group of exocyclic amine of nucleobases (A and C) is benzhydryloxycarbonyl. FIGS. 24A-B show (A) HPLC and (B) MALDI-TOF profiles.
1005011 EXAMPLE 100 - Synthesis of PNA oligomer sequence H2N-ACCCTACTGT-H (SEQ ID NO:9)
[00502] The title sequence was synthesized manually by the above general procedure using monomer of general formula I, wherein Rl, R2, R3, R4, and R5 are H and the protecting group of exocyclic amine of nucleobases (A, C, and G) is benzhydryloxycarbonyl. FIGS. 25A-B show (A) HPLC and (B) MALDI-TOF profiles.
*****
100503] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention specifically described herein. Such equivalents are intended to be encompassed in the scope of the claims.














We claim: 1. A compound having formula I:
(Formula Removed)
wherein
E is nitrogen or C-R'; J is sulfur or oxygen;
R', R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl,
halogenated alkoxy, phenyl or halogenated phenyl;
R5 is H or protected or unprotected side chain of natural or unnatural a-amino acid; and
B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic
amino function, said function is protected by protecting group having a formula;
(Formula Removed)
wherein R7 has a formula;
(Formula Removed)
wherein Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10 is independently selected from hydrogen, halogen, alkyl, and alkoxy; or
(Formula Removed)
wherein Z1, Z2, Z3, Z4, Z5 is independently selected from hydrogen, halogen, alkyl, alkoxy, and methylene dioxy of adjacent two residues; or
(Formula Removed)
wherein R8 is alkyl or phenyl.
2. The compound as claimed in claim 1, wherein E is nitrogen and J is sulfur.
3. The compound as claimed in claim 1, wherein E is nitrogen and J is oxygen.
4. The compound of claim 1, wherein E is CH and J is sulfur.
5. The compound as claimed in claim 1, wherein E is CH and J is oxygen.
6. The compound as claimed in claim 1, wherein R5 is H or protected or unprotected side chain of natural a-amino acid.
7. The compound as claimed in claim 1, wherein R' is H, CF3, F, CI, Br, I, methyl, phenyl, nitro, or nitrile.
8. The compound as claimed in claim 1, wherein B is thymine (T), cytosine (C), adenine (A), or guanine (G).
9. The compound as claimed in claim 1, wherein said protecting group for the exocyclic amino function of B is benzyloxycarbonyl, benzhydryloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, piperonyloxycarbonyl derivatives, or 2- methylthioethoxycarbonyl.

10. The compound as claimed in claim 1, wherein R1, R2, R3, and R4 are H.
11. The compound as claimed in claim 1, wherein R2 is CI, and Rl, R3 and R4 are H.
12. The compound as claimed in claim 1, wherein R1 is CI, R2 is methoxy, and R3, R4 and R5
are H.
13. The compound as claimed in claim 1, wherein Rl, R2, R3, and R4 are H; E is nitrogen; and
J is sulfur.
14. A method of making the compound as claimed in claim 1, comprising cyclizing a
compound of formula VI in the presence of a coupling reagent that is customarily used in
peptide synthesis or mixed anhydride, wherein the formula VI is represented as follows:

(Formula Removed)
wherein
E is nitrogen or C-R'; J is sulfur or oxygen;
R', R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl,
halogenated alkoxy, phenyl or halogenated phenyl;
R5 is H or protected or unprotected side chain of natural or unnatural a-amino acid; and
B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic
amino function, said function is protected by protecting group having a formula;
(Formula Removed)
wherein R7 has a formula;
(Formula Removed)
wherein Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10 is independently selected from hydrogen, halogen, alkyl, and alkoxy; or
(Formula Removed)
wherein Z1, Z2, Z3, Z4, Z5 is independently selected from hydrogen, halogen, alkyl, alkoxy, and methylene dioxy of adjacent two residues; or
(Formula Removed)
wherein R8 is alkyl or phenyl. 15. A compound having formula V
(Formula Removed)
wherein
E is nitrogen or C-R'; J is sulfur or oxygen;
R', R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl,
halogenated alkoxy, phenyl or halogenated phenyl;
R5 is H or protected or unprotected side chain of natural or unnatural α-amino acid;
R6 is H, alkyl, or aryl; and
B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic
amino function, said function is protected by protecting group having a formula;
(Formula Removed)
wherein R7 has a formula;
(Formula Removed)
wherein Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10 is independently selected from hydrogen, halogen, alkyl, and alkoxy; or
(Formula Removed)
wherein Z1, Z2, Z3, Z4, Z5 is independently selected from hydrogen, halogen, alkyl, alkoxy, and methylene dioxy of adjacent two residues; or
(Formula Removed)
wherein R8 is alkyl or phenyl.
16. The compound as claimed in claim 15, wherein R6 is methyl, ethyl or t-butyl.
17. The compound as claimed in claim 15, wherein the protecting group for the exocyclic
amino function of B is benzyloxycarbonyl, benzhydryloxycarbonyl, 4-
methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, piperonyloxycarbonyl
derivatives, or 2- methylthioethoxycarbonyl.
18. A method of making the compound as claimed in claim 15, comprising coupling reaction
of a compound of formula II with a nucleobase acetic acid moiety in the presence of non-
nucleophilic organic base and a coupling reagent that is customarily used in peptide synthesis, wherein formula II is represented as follows:
(Formula Removed)
wherein
E is nitrogen or C-R'; J is sulfur or oxygen;
R', R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl,
halogenated alkoxy, phenyl or halogenated phenyl;
R5 is H or protected or unprotected side chain of natural or unnatural a-amino acid; and
R6 is H, alkyl, or aryl,
wherein said nucleobase acetic acid moiety is represented as follows:
(Formula Removed)
wherein
B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic
amino function, said function is protected by protecting group.
19. A method of making PIMA oligomer, comprising linking together the compound of claim 1.
20. An oligomer comprising the compound of claim 1.

Documents:

3299-DELNP-2004-Abstract-(24-02-2010).pdf

3299-delnp-2004-abstract.pdf

3299-DELNP-2004-Claims-(13-08-2010).pdf

3299-DELNP-2004-Claims-(18-09-2008).pdf

3299-DELNP-2004-Claims-(24-02-2010).pdf

3299-delnp-2004-claims.pdf

3299-delnp-2004-Correspondence-Others (01-12-2009).pdf

3299-DELNP-2004-Correspondence-Others-(13-08-2010).pdf

3299-DELNP-2004-Correspondence-Others-(24-02-2010).pdf

3299-delnp-2004-correspondence-others.pdf

3299-DELNP-2004-Description (Complete)-(18-09-2008).pdf

3299-DELNP-2004-Description (Complete)-(24-02-2010).pdf

3299-DELNP-2004-Drawings-(24-02-2010).pdf

3299-delnp-2004-drawings.pdf

3299-DELNP-2004-Form-1-(24-02-2010).pdf

3299-DELNP-2004-Form-1.pdf

3299-delnp-2004-form-18.pdf

3299-DELNP-2004-Form-2-(18-09-2008).pdf

3299-DELNP-2004-Form-2-(24-02-2010).pdf

3299-delnp-2004-form-2.pdf

3299-delnp-2004-Form-3 (01-12-2009).pdf

3299-DELNP-2004-Form-3-(24-02-2010).pdf

3299-DELNP-2004-Form-3.pdf

3299-delnp-2004-form-5.pdf

3299-delnp-2004-gpa.pdf

3299-delnp-2004-pct-210.pdf

3299-DELNP-2004-Petition 137-(24-02-2010).pdf

3299-DELNP-2004-Petition 138-(24-02-2010).pdf


Patent Number 243570
Indian Patent Application Number 3299/DELNP/2004
PG Journal Number 44/2010
Publication Date 29-Oct-2010
Grant Date 26-Oct-2010
Date of Filing 25-Oct-2004
Name of Patentee PANAGENE, INC.
Applicant Address 100 SINGUNG-DONG, YUSUN-GU, DAEJEON 305-345, KOREA.
Inventors:
# Inventor's Name Inventor's Address
1 KIM SUNG KEE 110-106, HANBIT APT., EOUN-DONG, YUSEONG-GU, DAEJEON 305-755, KOREA.
2 LEE HYUNIL 110-403, HANWOOL APT., SINGSUNG-DONG, YUSEONG-GU, DAEJEON 305-707, KOREA.
3 LIM JONG CHAN 103-203,HANA APT., SINSUNG-DONG, YUSEONG-GU, DAEJEON 305-721, KOREA.
4 CHOI HOON 339-17, JEONMIN-DONG, YUSEONG-GU, DAEJEON 305-810 KOREA.
5 YOON WON JUN 2-808, SINDONGAH APT., BANGBAE-DONG, SEOCHU-GU,SEOUL 137-758, KOREA.
6 JEON JAE HOON 106-202, CHEONGGU NARAE APT., JEONMIN-DONG, YUSEONG-GU, DAEJEON 305-729, KOREA.
7 AHN SANG YOUL 308-403, SONGGANG GREEN APT., SONGGANG-DONG, YUSEONG-GU, DAEJEON 305-751, KOREA.
8 LEE SUNG HEE 103-1502, JUGONG APT., JOWON-DONG, JANGAN-GU, SUWON, KYUNFFI-DO 440-716, KOREA.
PCT International Classification Number C07D 277/76
PCT International Application Number PCT/IB03/01595
PCT International Filing date 2003-04-28
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 2002/23157 2002-04-26 Republic of Korea